



diginerve
A Jaypee Initiative

Your Guide at Every Step
Video Lectures | Notes | Self-Assessment



Scan code
to check out
courses

PG Textbook of **PEDIATRICS**

Look Inside the Book

*This book is printed
in 3 volumes*

VOLUME 1
**GENERAL PEDIATRICS,
INTENSIVE CARE,
AND NEONATOLOGY**

3rd Edition

Piyush Gupta
PSN Menon
Siddarth Ramji
Rakesh Lodha

Contents

VOLUME 1

General Pediatrics, Intensive Care, and Neonatology

PART I

PEDIATRICS: YESTERDAY, TODAY, AND TOMORROW

SECTION 1

INTRODUCTION TO PEDIATRICS

Section Editor: **Piyush Gupta**

- | | |
|--|---|
| 1.1 Evolution of Pediatrics 3
<i>KN Agarwal</i> | 1.4 Ethical Issues in Pediatrics 24
<i>Sanjiv Lewin</i> |
| 1.2 Child Health: Concepts and Concerns 7
<i>Piyush Gupta, Neha Thakur</i> | 1.5 Sustainable Development Goals for Child Health 27
<i>Raju C Shah, Pratima Shah</i> |
| 1.3 Evidence-based Care in Pediatrics 19
<i>Joseph L Mathew</i> | |

PART II

BASIC SCIENCES AS APPLIED TO PEDIATRICS

SECTION 2

GENETICS AND GENETIC DISORDERS

Section Editor: **Shubha R Phadke**

- | | |
|---|--|
| 2.1 Gene, Genome, and Genetic Basis of Diseases 35
<i>Girisha KM</i> | 2.4 Chromosomal Disorders 58
<i>Shagun Aggarwal, Ashwin Dalal</i> |
| 2.2 Patterns of Inheritance 42
<i>Prajnya Ranganath, Shubha R Phadke</i> | 2.5 Management of Genetic Disorders and Genetic Counseling 70
<i>Shubha R Phadke</i> |
| 2.3 Clinical Dysmorphology: An Approach to Bedside Diagnosis 51
<i>Ratna Dua Puri</i> | 2.6 Prevention of Genetic Disorders 77
<i>Neerja Gupta, Madhulika Kabra</i> |

SECTION 3

METABOLIC DISORDERS

Section Editors: **Madhulika Kabra, Neerja Gupta**

- | | |
|--|--|
| 3.1 Approach to Inborn Errors of Metabolism 82
<i>Chitra Prasad, Mark Korson, CA Rupar</i> | 3.3 Urea Cycle Disorders 104
<i>Sunita Bijarnia-Mahay</i> |
| 3.2 Defects of Amino Acid Metabolism 91
<i>Anil B Jalan, Ketki V Kudalkar, Rishikesh A Jalan</i> | 3.4 Organic Acidemias 111
<i>Neerja Gupta, Madhulika Kabra</i> |

3.5 Fatty Acid Oxidation Defects	118	3.13 Defects of Carbohydrate Metabolism	165
<i>Manisha Goyal, Ranjana Mishra, Seema Kapoor</i>		<i>Kausik Mandal</i>	
3.6 Mitochondrial Disorders	122	3.14 Glycogen Storage Diseases	172
<i>Sheffali Gulati, Biswaroop Chakrabarty, Gautam Kamila</i>		<i>Ghada Hijazi, Priya S Kishnani</i>	
3.7 Peroxisomal Disorders	128	3.15 Pompe Disease	177
<i>Madhulika Kabra, Neerja Gupta</i>		<i>Ghada Hijazi, Sireesha Murala, Priya S Kishnani</i>	
3.8 Lysosomal Storage Disorders	132	3.16 Mucopolysaccharidoses	182
<i>Ishwar C Verma, Veronica Arora</i>		<i>Girisha KM</i>	
3.9 GM1 and GM2 Gangliosidosis	141	3.17 Approach to Hypoglycemia	187
<i>Parag M Tamhankar</i>		<i>Meenakshi Bothra Gupta, Vandana Jain</i>	
3.10 Gaucher Disease	145	3.18 Porphyrrias	194
<i>Mamta Muranjan</i>		<i>Meenal Agarwal, Shubha R Phadke</i>	
3.11 Niemann-Pick Disease	156	3.19 Newborn Screening	199
<i>Ashwin Dalal</i>		<i>Seema Kapoor, Meenakshi Bothra Gupta, Madhulika Kabra</i>	
3.12 Fabry Disease	160		
<i>Ratna Dua Puri</i>			

SECTION 4**IMMUNITY, IMMUNE DISORDERS, AND ALLERGY**Section Editors: **Surjit Singh, Amit Rawat**

4.1 Basics of Immunology	203	4.5 Intravenous Immunoglobulin	231
<i>Amit Rawat, Biman Saikia</i>		<i>Sujoy Khan, Surjit Singh</i>	
4.2 Laboratory Diagnosis of Immune-mediated Diseases	208	4.6 Basis of Allergy	236
<i>Biman Saikia, Deepti Suri</i>		<i>Sujoy Khan</i>	
4.3 Primary Immunodeficiency Disorders/Inborn Errors of Immunity	217	4.7 Diagnosis and Management of Allergic Disorders	241
<i>Manisha Madhakar, Jahnavi Aluri, Maya Gupta</i>		<i>Sujoy Khan, Amit Rawat</i>	
4.4 Approach to Diagnosis and Management of Primary Immunodeficiency Disorders	227		
<i>Revathi Raj, Surjit Singh</i>			

SECTION 5**FLUID AND ELECTROLYTES**Section Editor: **Rakesh Lodha**

5.1 Body Fluids	248	5.5 Sodium and Related Disorders	268
<i>Raghuvamsi Chaitra, Suchitra Ranjit</i>		<i>Andrew C Argent, Mignon I McCulloch</i>	
5.2 Fluid Therapy	252	5.6 Potassium	273
<i>Banani Poddar, Kirti M Naranje</i>		<i>Virendra Kumar, Abhijeet Saha</i>	
5.3 Acid-base Equilibrium	258	5.7 Magnesium Balance	278
<i>Dinesh Raj, Rakesh Lodha</i>		<i>Virendra Kumar</i>	
5.4 Abnormalities of Acid-base Balance	263		
<i>Dinesh Raj, Rakesh Lodha</i>			

SECTION 6**DRUGS AND THERAPEUTICS**Section Editor: **Sandeep B Bavdekar**

6.1 Principles of Drug Therapy	282	6.2 Administration of Medications	287
<i>Sandeep B Bavdekar</i>		<i>Jeeson C Unni</i>	

PART III

INTENSIVE CARE AND EMERGENCIES

SECTION 7

ACUTELY ILL CHILD AND RESUSCITATION

Section Editor: **Rakesh Lodha**

- | | |
|---|---|
| 7.1 Assessment and Triage299 | 7.3 Basic Life Support308 |
| <i>M Jayashree, Sunit Singhi</i> | <i>Shalu Gupta</i> |
| 7.2 Cardiopulmonary Resuscitation302 | 7.4 Pediatric Advanced Life Support312 |
| <i>Utpal Bhalala, Vijay Srinivasan</i> | <i>Javed Ismail, Banani Poddar</i> |

SECTION 8

INTENSIVE CARE

Section Editor: **Rakesh Lodha**

- | | |
|--|---|
| 8.1 Pediatric Intensive Care Unit324 | 8.4 Pediatric Acute Respiratory Distress Syndrome343 |
| <i>Dhiren Gupta, Neeraj Gupta, Manpreet Sethi</i> | <i>Venkat Shankar</i> |
| 8.2 Shock328 | 8.5 Mechanical Ventilation349 |
| <i>Padma Venkatasubbu, Srinivas Murthy, Niranjan Kissoon</i> | <i>Dinesh Raj, Rakesh Lodha</i> |
| 8.3 Respiratory Failure336 | 8.6 Sedation and Analgesia360 |
| <i>Lokesh Guglani</i> | <i>Venkat Shankar</i> |

SECTION 9

POISONING AND ENVENOMATION

Section Editor: **Rakesh Lodha**

- | | |
|---|---|
| 9.1 Clinical Approach to a Poisoned Child365 | 9.5 Corrosive Poisoning390 |
| <i>P Ramesh Menon, Vijesh S Kuttiatt</i> | <i>Urmila Jhamb</i> |
| 9.2 Poisonings by Common Drugs371 | 9.6 Snakebite394 |
| <i>Indumathy Santhanam, Sharada Sathish</i> | <i>R Rameshkumar, S Mahadevan</i> |
| 9.3 Hydrocarbon Poisoning379 | 9.7 Scorpion Sting404 |
| <i>M Jayashree, Karthi N</i> | <i>R Rameshkumar, S Mahadevan</i> |
| 9.4 Poisoning in the Household382 | |
| <i>Narayanan P, Hari Krishnan KN</i> | |

SECTION 10

CHILDHOOD INJURIES

Section Editor: **Rakesh Lodha**

- | | |
|---|---|
| 10.1 Trauma: Stabilization, Triage, and Transport411 | 10.4 Burn Injuries425 |
| <i>Mukuka Kangwa, Shruti Kant, Manu Madhok</i> | <i>K Mathangi Ramakrishnan, V Jayaraman,</i> |
| 10.2 Drowning/Submersion Injuries417 | <i>T Mathivanan, V Srinivasan</i> |
| <i>Arun Bansal</i> | 10.5 Cold Injuries434 |
| 10.3 Animal-related Injuries420 | <i>Deeksha Borkar, Shruti Kant, Manu Madhok</i> |
| <i>Arun Kumar Baranwal, Lalit Takia</i> | |

PART IV

THE NEWBORN INFANT

SECTION 11

NEONATAL PHYSIOLOGY AND ORGANIZATION OF CARE

Section Editor: **Siddarth Ramji**

- | | |
|---|--|
| 11.1 Neonatal Mortality and Morbidities: An Overview443
<i>Aparna Chandrasekaran, M Jeeva Sankar</i> | 11.4 Transition of the Fetus to Newborn456
<i>Siddarth Ramji</i> |
| 11.2 Fetal Physiology and Growth.....449
<i>Deepak Chawla</i> | 11.5 Organization of Neonatal Care.....460
<i>Subhash Chandra Shaw, Ramesh Agarwal,
Vinod K Paul</i> |
| 11.3 Maternal Influences on Fetus453
<i>Roopa M Bellad</i> | |

SECTION 12

NORMAL NEWBORN

Section Editor: **Siddarth Ramji**

- | | |
|--|---|
| 12.1 Delivery Room Care of the Newborn465
<i>Siddarth Ramji</i> | 12.4 Maintenance of Temperature481
<i>Suksham Jain, Vimlesh Soni</i> |
| 12.2 Assessment of the Newborn.....470
<i>Harish Chellani, Sugandha Arya</i> | 12.5 Breastfeeding and Lactation Management488
<i>Sushma Nangia, Srishti Goel</i> |
| 12.3 Care of the Normal Newborn477
<i>Somashekhar Nimbalkar</i> | |

SECTION 13

DISORDERS OF WEIGHT AND GESTATION

Section Editor: **Siddarth Ramji**

- | | |
|--|---|
| 13.1 Low-birthweight: Classification and Etiology.....499
<i>Ruchi Nimish Nanavati</i> | 13.5 Postmaturity522
<i>Reeta Bora, Pranay Phukan</i> |
| 13.2 Prematurity and Intrauterine Growth Restriction.....503
<i>Ashok Kumar, Sriparna Basu</i> | 13.6 Large for Gestational Age.....525
<i>Rhishikesh Thakre</i> |
| 13.3 Feeding of Low-birthweight511
<i>Kanya Mukhopadhyay</i> | 13.7 Multiple Gestations.....529
<i>Mamta Jajoo</i> |
| 13.4 Long-term Outcome of Low-birthweight Infant.....517
<i>Suman Rao PN, Fathima Sabahath</i> | |

SECTION 14

HIGH-RISK NEWBORN

Section Editor: **Siddarth Ramji**

- | | |
|--|--|
| 14.1 Recognition of High-risk Neonate535
<i>Niranjan Thomas, Vijay Gupta</i> | 14.6 Anemia and Polycythemia.....571
<i>Venkateshan Sundaram, Bikramjit Das, Prateek Bhatia</i> |
| 14.2 Birth Injuries.....544
<i>Suksham Jain, Vimlesh Soni</i> | 14.7 The Bleeding Neonate583
<i>Shashi Kant Dhir</i> |
| 14.3 Jaundice in the Newborn551
<i>Sheila S Mathai, Kannan Venkatnarayan</i> | 14.8 Hemorrhagic Disease of Newborn587
<i>Shashi Kant Dhir</i> |
| 14.4 Infant of Diabetic Mother561
<i>Srinivas Murki, Tejo Pratap Oleti</i> | 14.9 Thrombocytopenia in the Newborn.....590
<i>Pradeep Sharma</i> |
| 14.5 Neonatal Hypoglycemia.....565
<i>Shiv Sajjan Saini, Praveen Kumar</i> | 14.10 Cyanosis in the Newborn593
<i>K Anil Kuruvilla, Vijay Gupta, Mintoo M Tergestina</i> |

14.11 Necrotizing Enterocolitis.....602	14.13 Neonatal Transport616
<i>Krishna Kumar Diwakar, Manu Rajan Idicula</i>	<i>Neelam Kler, Anup Thakur</i>
14.12 Retinopathy of Prematurity.....607	14.14 Follow-up of the High-risk Neonate623
<i>Ashish Jain, Parijat Chandra, Priyanka Meena</i>	<i>Pratima Anand, Shuchita Gupta</i>

SECTION 15**NEONATAL INFECTIONS**Section Editor: **Siddarth Ramji**

15.1 Neonatal Sepsis.....632	15.4 Deep-seated Infections in Neonates652
<i>Suman Chaurasia, Ramesh Agarwal</i>	<i>Natalie Gallagher, Kumutha Jayaraman, Manigandan Chandrasekaran</i>
15.2 Superficial Infections in Neonates639	15.5 Neonatal Tetanus658
<i>Sriparna Basu, Ashok Kumar</i>	<i>Mala Kumar, Shalini Tripathi</i>
15.3 Neonatal Meningitis.....645	15.6 Intrauterine Infections661
<i>Kumutha Jayaraman, Manigandan Chandrasekaran</i>	<i>Sriparna Basu, Ashok Kumar</i>

SECTION 16**NEUROLOGICAL PROBLEMS**Section Editor: **Siddarth Ramji**

16.1 Seizures in the Neonates670	16.3 Intraventricular Hemorrhage and White Matter Injury684
<i>Amit Upadhyay, Pranjali Saxena</i>	<i>Deepa Arun, Kathryn Hanson, Amit M Mathur</i>
16.2 Hypoxic Ischemic Encephalopathy676	
<i>B Vishnu Bhat, B Adhisivam</i>	

SECTION 17**RESPIRATORY PROBLEMS**Section Editor: **Siddarth Ramji**

17.1 Approach to a Neonate with Respiratory Distress.....693	17.6 Meconium Aspiration Syndrome719
<i>Swarna Rekha Bhat</i>	<i>Naveen Jain</i>
17.2 Neonatal Apnea696	17.7 Pulmonary Air Leaks in the Newborn721
<i>Manoj Modi</i>	<i>Manish Balde, Sanjay Wazir</i>
17.3 Neonatal Ventilation701	17.8 Persistent Pulmonary Hypertension of the Newborn727
<i>Sourabh Dutta</i>	<i>Neeraj Gupta, Bharti Yadav</i>
17.4 Hyaline Membrane Disease.....710	17.9 Pulmonary Hemorrhage735
<i>Praveen Kumar, Anuj Bhatti</i>	<i>Daniel Mammel, Rakesh Rao</i>
17.5 Transient Tachypnea of the Newborn716	17.10 Bronchopulmonary Dysplasia.....742
<i>Srinivas Murki</i>	<i>Sanoj KM Ali, Sunil K Sinha, Samir Gupta</i>

SECTION 18**MALFORMATIONS**Section Editor: **Siddarth Ramji**

18.1 Esophageal Atresia and Tracheoesophageal Fistula748	18.3 Gastrointestinal and Abdominal Malformations758
<i>Yogesh Kumar Sarin, Vikram Khanna</i>	<i>Satish Kumar Aggarwal, Sugandh Aggarwal, Garvita Singh</i>
18.2 Diaphragmatic Hernia and Eventration753	18.4 Genitourinary Malformations773
<i>Yogesh Kumar Sarin, Shalini Sinha</i>	<i>Satish Kumar Aggarwal</i>
	18.5 CNS Malformations.....783
	<i>Nidhi Sugandhi, Veereshwar Bhatnagar</i>

PART V

THE CHILDHOOD YEARS

SECTION 19

GROWTH: NORMAL AND ABNORMAL

Section Editor: **Anju Seth**

19.1 Normal Growth	795	19.5 Bone Age and Predicted Final Height	847
<i>Ruchi Mishra, Vandana Jain</i>		<i>M Vijayakumar, Anju Seth</i>	
19.2 Factors Affecting Growth	800	19.6 Failure to Thrive	851
<i>Devi Dayal, Saniya Gupta</i>		<i>Sudha Rao Chandrashekhar</i>	
19.3 Assessment of Physical Growth	804	19.7 Overweight and Obesity	856
<i>Anju Seth, Rajni Sharma</i>		<i>Rajesh Khadgawat, Aashima Dabas</i>	
19.4 Dental Development and Anomalies	836	19.8 Abnormalities of Stature	864
<i>Sunanda Roychoudhury, Shakil Ahmed Nagori, Poonam Yadav, Ajoy Roychoudhury</i>		<i>Meghna Chawla, Leena Patel, Maria Salomon-Estebanez</i>	

SECTION 20

DEVELOPMENT AND DEVELOPMENTAL DELAY

Section Editor: **Piyush Gupta**

20.1 Introduction to Development, Laws of Development, and Factors Affecting Development	878	20.4 Cerebral Palsy	896
<i>Satnam Kaur</i>		<i>Sharmila Banerjee Mukherjee, Dipti Kapoor</i>	
20.2 Normal Development	882	20.5 Global Developmental Delay	908
<i>Ujjwal Nene</i>		<i>Madhuri Kulkarni, Mona P Gajre</i>	
20.3 Approach to Diagnosis of Developmental Delay: Developmental Screening and Surveillance	889	20.6 Intellectual Disability	913
<i>Sudha Chaudhari</i>		<i>Suja Koshy, Zainab Farooqui</i>	
		20.7 Hearing Impairment	923
		<i>Neelam Vaid</i>	

SECTION 21

BEHAVIOR AND LEARNING

Section Editors: **Monica Juneja, Devendra Mishra**

21.1 Moral Development	929	21.9 Attention-deficit Hyperactivity Disorder	957
<i>Prahbjot Malhi, Rajalakshmi Iyer</i>		<i>Rajesh Sagar, Rohit Verma</i>	
21.2 Evaluation of Mental Well-being	932	21.10 Oppositional Defiant and Conduct Disorders	964
<i>Manju Mehta, Sneha Kapoor</i>		<i>Rajesh Sagar, Rajeev Ranjan</i>	
21.3 Common Behavioral Problems	934	21.11 Autism Spectrum Disorder	969
<i>Praveen Suman</i>		<i>Monica Juneja, Rahul Jain</i>	
21.4 Breath-holding Spells	938	21.12 Rett Syndrome	975
<i>Sumaira Khalil, Devendra Mishra</i>		<i>Monica Juneja, Rajni Khajuria</i>	
21.5 Encopresis	940	21.13 Anorexia Nervosa and Bulimia	978
<i>Piyush Gupta, Ruchi Mishra</i>		<i>Koushik Sinha Deb, Rajesh Sagar</i>	
21.6 Sleep Medicine	942	21.14 Anxiety Disorders	983
<i>Suresh Kotagal</i>		<i>Preeti Kandasamy, Shoba Srinath</i>	
21.7 Common Speech, Language, and Communication Disorders	948	21.15 Management of Psychological Illness	985
<i>Prathibha Karanth</i>		<i>Paul Russell</i>	
21.8 Learning Disorders	954		
<i>Nandini Mundkur, Chitra Sankar</i>			

SECTION 22

NUTRITION AND NUTRITIONAL DISORDERS

Section Editors: **KE Elizabeth, Piyush Gupta**

22.1 Nutrient Groups and Nutritional Requirements989	22.11 Vitamin C and Scurvy 1056
<i>KE Elizabeth, S Bindusha</i>	<i>Shaveta Kundra, Tejinder Singh</i>
22.2 Nutritive Values of Foods995	22.12 Vitamin D, Nutritional Rickets, and Hypervitaminosis D 1059
<i>Neetu Sharma, Piyush Gupta</i>	<i>S Balasubramanian, Piyush Gupta</i>
22.3 Infant and Young Child Feeding 1006	22.13 Iodine Deficiency Disorders 1065
<i>JP Dadhich</i>	<i>Umesh Kapil, Neha Sareen</i>
22.4 Feeding during Childhood and Food Allergy 1011	22.14 Zinc in Child Health 1068
<i>KE Elizabeth, S Bindusha</i>	<i>Shashi Ajit Chiplonkar</i>
22.5 Undernutrition: Prevalence and Etiology 1016	22.15 Trace Elements in Nutrition and Health 1073
<i>Piyush Gupta, Neetu Sharma</i>	<i>P Leelakumari, KE Elizabeth</i>
22.6 Pathophysiology of Undernutrition 1030	22.16 Fluorosis 1077
<i>OP Mishra</i>	<i>Sunil Kumar Gupta</i>
22.7 Protein-energy Malnutrition 1033	22.17 Enteral and Parenteral Nutrition 1083
<i>KE Elizabeth, Sheeja Sugunan</i>	<i>Vikram Bhaskar</i>
22.8 Severe Acute Malnutrition 1038	22.18 Nutrition in the 21st Century 1089
<i>Praveen Kumar, Preeti Singh</i>	<i>Gouri Rao Passi, Neha Ahuja, Piyush Gupta</i>
22.9 Vitamin A 1046	22.19 National Nutrition Programs 1093
<i>Neetu Sharma, Piyush Gupta</i>	<i>Dipty Jain, Saira Merchant</i>
22.10 Vitamin B Complex Deficiency 1052	
<i>Vineeta Gupta</i>	

SECTION 23

IMMUNIZATION

Section Editor: **Vipin M Vashishtha**

23.1 Basic Concepts of Vaccination 1098	23.12 Rubella Vaccines 1152
<i>Chandrakant Lahariya</i>	<i>Nabaneeta Dash, Sanjay Verma</i>
23.2 Vaccine Administration Practices 1107	23.13 Mumps Vaccine 1156
<i>Satish V Pandya</i>	<i>Aashima Dabas</i>
23.3 Scheduling of Vaccines 1112	23.14 Typhoid Fever Vaccines 1158
<i>Vipin M Vashishtha</i>	<i>Sushant Sahastrabuddhe, Mohammad Imran Khan, Tarun Saluja</i>
23.4 Vaccine Storage and Cold Chain 1116	23.15 Japanese Encephalitis Vaccines 1162
<i>Karan Singh Sagar, Manish Jain</i>	<i>VG Ramachandran, Chabungbam Smilie</i>
23.5 Adverse Events following Immunization 1123	23.16 Rabies Vaccines 1164
<i>Ajay Kalra, Vipin M Vashishtha</i>	<i>Anuradha Bose</i>
23.6 BCG Vaccine 1129	23.17 Pneumococcal Vaccines 1167
<i>Sangeeta Sharma</i>	<i>Puneet Kumar, Vipin M Vashishtha</i>
23.7 Poliovirus Vaccines 1134	23.18 Rotavirus Vaccines 1172
<i>Puneet Kumar, Vipin M Vashishtha</i>	<i>Gagandeep Kang</i>
23.8 Diphtheria, Tetanus, and Pertussis Vaccines 1139	23.19 Cholera Vaccines 1174
<i>Puneet Kumar, Vipin M Vashishtha</i>	<i>Monjori Mitra</i>
23.9 Hepatitis B Vaccine 1144	23.20 Varicella Vaccine 1176
<i>Ajay Kalra</i>	<i>Rakesh Kumar</i>
23.10 Haemophilus Influenzae Type B Vaccines 1147	23.21 Hepatitis A Vaccine 1178
<i>AK Patwari</i>	<i>Bharat Mehra, AJ Chitkara</i>
23.11 Measles Vaccine 1149	
<i>Vimlesh Soni, Sanjay Verma</i>	

23.22 Meningococcal Vaccine 1180 <i>Jaydeep Choudhury</i>	23.26 Dengue Vaccines 1201 <i>Jacqueline K Lim, In-Kyu Yoon</i>
23.23 Seasonal and Pandemic Influenza Vaccines 1182 <i>Shobha Broor</i>	23.27 Yellow Fever Vaccine 1206 <i>Parang N Mehta</i>
23.24 Coronavirus Vaccines 1187 <i>Puneet Kumar, Vipin M Vashishtha</i>	23.28 Combination Vaccines 1208 <i>Niranjan Shendurnikar, Shwetal Bhatt</i>
23.25 Human Papillomavirus Vaccines 1195 <i>Srinivas G Kasi</i>	23.29 Immunization in Special Situations 1211 <i>Piyali Bhattacharya, Utkarsh Bansal</i>

VOLUME 2

Adolescent Health, Infectious Diseases, and Systemic Pediatrics

PART VI

ADOLESCENT HEALTH

SECTION 24

ADOLESCENT DEVELOPMENT

Section Editor: **MKC Nair**

24.1 Adolescence and Adolescent 1221 <i>MKC Nair, Paul Russell</i>	24.3 Psychosocial Development 1231 <i>Yamuna S</i>
24.2 Sexual Development and Sexuality 1226 <i>Chandrika Rao</i>	

SECTION 25

HEALTH ISSUES IN ADOLESCENCE

Section Editor: **MKC Nair**

25.1 Factors Influencing Adolescent Health 1237 <i>Sukanta Chatterjee</i>	25.5 Menstrual Disorders and Polycystic Ovary Syndrome 1263 <i>Amita Suneja, Richa Aggarwal</i>
25.2 Adolescent Nutrition 1242 <i>Preeti M Galagali</i>	25.6 Teenage Pregnancy 1272 <i>Richa Aggarwal, Amita Suneja</i>
25.3 Mental Health 1250 <i>Priya Mary Mammen</i>	25.7 Sexually Transmitted Infections 1274 <i>Newton Luiz</i>
25.4 Injuries, Violence, and Suicide 1256 <i>Srikanta Basu</i>	

SECTION 26

CARE OF THE ADOLESCENTS

Section Editor: **MKC Nair**

26.1 Adolescent Counseling 1281 <i>Atul M Kanikar</i>	26.3 Adolescent Friendly Health Services 1294 <i>Rajesh Mehta, Neena Raina, Patanjali Dev Nayar</i>
26.2 Promoting Health of Adolescents 1289 <i>Harish K Pemde, Kamlesh Harish</i>	

PART VII

INFECTIOUS DISEASES

SECTION 27

BASIC CONCEPTS

Section Editors: **Piyush Gupta, Jaydeep Choudhury**

- | | |
|--|---|
| 27.1 Epidemiology of Infectious Diseases 1301 | 27.4 Antimicrobial Resistance 1316 |
| <i>VG Ramachandran, Chabungbam Smilie, Piyush Gupta</i> | <i>Anuradha De</i> |
| 27.2 Laboratory Diagnosis of Infection 1307 | 27.5 Infection Control and Prevention 1324 |
| <i>Sankar Sengupta</i> | <i>Jaydeep Choudhury</i> |
| 27.3 Microbiome and Child Health 1312 | |
| <i>Shilpa Khanna Arora, Pooja Dewan, Piyush Gupta</i> | |

SECTION 28

FEVER

Section Editor: **Piyush Gupta**

- | | |
|--|--|
| 28.1 Approach to a Child with Fever 1330 | 28.3 Fever without Focus 1336 |
| <i>Bhavna Dhingra, Piyush Gupta</i> | <i>Piyush Gupta, Bhavna Dhingra</i> |
| 28.2 Fever: General Principles of Management 1333 | 28.4 Fever of Unknown Origin 1338 |
| <i>Piyush Gupta, Bhavna Dhingra</i> | <i>Bhavna Dhingra, Piyush Gupta</i> |

SECTION 29

BACTERIAL INFECTIONS

Section Editors: **Jaydeep Choudhury, Piyush Gupta**

- | | |
|---|---|
| 29.1 Natural History of Bacterial Infection 1341 | 29.12 <i>Neisseria</i> Infections 1390 |
| <i>VG Ramachandran, Chabungbam Smilie, Piyush Gupta</i> | <i>Vidushi Mahajan</i> |
| 29.2 Principles of Antibiotic Therapy 1344 | 29.13 <i>Pseudomonas</i> Infections 1394 |
| <i>Anita Shet, Kayur Mehta</i> | <i>Nupur Ganguly</i> |
| 29.3 Diphtheria 1353 | 29.14 Leptospirosis 1399 |
| <i>Purna Batra, Piyush Gupta</i> | <i>Janani Sankar</i> |
| 29.4 Pertussis 1357 | 29.15 Plague 1402 |
| <i>Piyush Gupta, Purna Batra</i> | <i>Utkarsh Sharma, Piyush Gupta</i> |
| 29.5 Tetanus 1360 | 29.16 Brucellosis 1405 |
| <i>Jaydeep Choudhury</i> | <i>Sriram Krishnamurthy, Sivamurukan Palanisamy</i> |
| 29.6 Typhoid Fever 1363 | 29.17 Relapsing Fever 1410 |
| <i>Apurba Ghosh, Monjori Mitra</i> | <i>P Ramachandran</i> |
| 29.7 Nontyphoidal Salmonellosis 1368 | 29.18 Lyme Disease 1413 |
| <i>Thangavelu Sangaralingam, Janani Ravi</i> | <i>P Ramachandran</i> |
| 29.8 <i>Haemophilus Influenzae</i> B Infections 1372 | 29.19 Nocardiosis 1415 |
| <i>Somu Sivabalan</i> | <i>Subhasish Bhattacharyya</i> |
| 29.9 Pneumococcal Diseases 1375 | 29.20 Actinomycosis 1417 |
| <i>Nishant Jaiswal, Meenu Singh, Manvi Singh</i> | <i>Subhasish Bhattacharyya</i> |
| 29.10 Streptococcal Infections 1379 | 29.21 <i>Helicobacter pylori</i> 1419 |
| <i>Pramod Sharma</i> | <i>John Matthai, Sarah Paul</i> |
| 29.11 Staphylococcal Infections 1383 | 29.22 Anaerobic Infections 1422 |
| <i>Zaki Syed</i> | <i>GV Basavaraja, Chiranth SB</i> |

SECTION 30

MYCOBACTERIAL INFECTIONS

Section Editor: **Rakesh Lodha**

- | | |
|---|--|
| <p>30.1 Childhood Tuberculosis: Epidemiology, Pathogenesis, Clinical Features, and Prevention 1427</p> <p><i>Banurekha Velayutham, Vineet Kumar Chadha, Soumya Swaminathan</i></p> <p>30.2 Diagnostic Tools for Tuberculosis in Children 1435</p> <p><i>NS Gomathi</i></p> <p>30.3 Antitubercular Drugs and NTEP Guidelines for Treatment of Childhood Tuberculosis 1440</p> <p><i>Varinder Singh, Deonath Mahto</i></p> | <p>30.4 Drug-resistant Tuberculosis 1446</p> <p><i>Rupak Singla, Amitesh Gupta, Aparna Mukherjee</i></p> <p>30.5 Atypical Mycobacterial Infections in Children 1455</p> <p><i>Priya Rajendran, C Padmapriyadarshni</i></p> <p>30.6 Leprosy 1462</p> <p><i>Rajeshwar Dayal, Manoj Kumar Singh, Sachin Chawla</i></p> |
|---|--|

SECTION 31

VIRAL DISEASES

Section Editors: **Ashok Kumar Dutta, Piyush Gupta**

- | | |
|--|---|
| <p>31.1 Epidemiology of Viral Infections 1467</p> <p><i>VG Ramachandran, Chabungbam Smilie, Piyush Gupta</i></p> <p>31.2 Antiviral Drugs in Pediatric Practice 1470</p> <p><i>Sanjiv Lewin, Indumathi CK, Maria L Lewin</i></p> <p>31.3 Measles 1474</p> <p><i>Shilpa Khanna Arora, Piyush Gupta</i></p> <p>31.4 Mumps 1479</p> <p><i>Shilpa Khanna Arora, Piyush Gupta</i></p> <p>31.5 Rubella 1482</p> <p><i>Pooja Dewan, Piyush Gupta</i></p> <p>31.6 Roseola Infections 1485</p> <p><i>Swati Singhal</i></p> <p>31.7 Infectious Mononucleosis 1488</p> <p><i>Rashmi Ranjan Das</i></p> <p>31.8 Influenza 1492</p> <p><i>Sonal Kansra, Alison Scott, Chukwudumebi Duru</i></p> <p>31.9 Varicella 1496</p> <p><i>Piyush Gupta, Aashima Dabas</i></p> <p>31.10 Herpes Simplex Infections 1501</p> <p><i>Niranjan Mohanty, Pradeep S</i></p> <p>31.11 Rabies 1505</p> <p><i>Jaydeep Choudhury</i></p> | <p>31.12 Parvovirus Infections 1509</p> <p><i>Anu Maheshwari</i></p> <p>31.13 Coronavirus, Coronavirus Disease-19, and Multi-inflammatory Syndrome in Children 1514</p> <p><i>S Balasubramanian, Tanu Singhal, Divya Nandakumar</i></p> <p>31.14 Nonpolio Enteroviral Infections 1529</p> <p><i>Annapurna Sudarsanam</i></p> <p>31.15 Poliomyelitis 1536</p> <p><i>Ashok Kumar Dutta</i></p> <p>31.16 Viral Hepatitis 1539</p> <p><i>Amit Goel, Chhavi Nanda</i></p> <p>31.17 HIV and Acquired Immunodeficiency Syndrome 1544</p> <p><i>Chhaya A Divecha, Milind S Tullu</i></p> <p>31.18 Japanese Encephalitis 1563</p> <p><i>Rashmi Kumar, Piyush Tripathi</i></p> <p>31.19 Dengue 1567</p> <p><i>Piyush Gupta, Aashima Dabas</i></p> <p>31.20 Chikungunya Fever 1577</p> <p><i>Rajni Prasad</i></p> <p>31.21 Viral Hemorrhagic Fevers 1580</p> <p><i>Nigam Prakash Narain, Priya Verma</i></p> |
|--|---|

SECTION 32

PROTOZOAL INFECTIONS AND INFESTATIONS

Section Editors: **Ritabrata Kundu, Piyush Gupta**

- | | |
|---|---|
| <p>32.1 Epidemiology of Parasitic Infections 1584</p> <p><i>Piyush Gupta, Chabungbam Smilie</i></p> <p>32.2 Malaria 1587</p> <p><i>Ritabrata Kundu</i></p> <p>32.3 Leishmaniasis 1595</p> <p><i>Shyam Sundar, Jaya Chakravarty</i></p> <p>32.4 Amebiasis 1601</p> <p><i>Piyush Gupta, Aashima Dabas</i></p> | <p>32.5 Giardiasis 1606</p> <p><i>Aashima Dabas, Piyush Gupta</i></p> <p>32.6 Cryptosporidiosis 1609</p> <p><i>Aashima Dabas, Piyush Gupta</i></p> <p>32.7 Ascariasis 1611</p> <p><i>Sutapa Ganguly</i></p> <p>32.8 Hookworm Infestation 1615</p> <p><i>Maitreyi Basu, Sutapa Ganguly</i></p> |
|---|---|

32.9 Trichuriasis 1617 <i>Manish Narang</i>	32.14 Intestinal, Liver, and Lung Flukes 1631 <i>Vikas Jain</i>
32.10 Enterobiasis 1619 <i>Dhrubajyoti Mridha, Sutapa Ganguly</i>	32.15 Tapeworm Diseases 1635 <i>Ruchi Rai</i>
32.11 Strongyloidiasis 1621 <i>Ravi Ambey, Tripty Naik</i>	32.16 Hydatid Disease: Echinococcosis 1639 <i>SK Gupta</i>
32.12 Trichinosis 1624 <i>Akash Bang, Puja Hingorani</i>	32.17 Schistosomiasis 1643 <i>Ritabrata Kundu, Devdeep Mukherjee</i>
32.13 Filariasis 1627 <i>Ajay Gaur</i>	

SECTION 33**FUNGAL INFECTIONS**Section Editor: **Piyush Gupta**

33.1 Fungi 1646 <i>VG Ramachandran, Chabungbam Smilie, Piyush Gupta</i>	33.6 Coccidioidomycosis 1663 <i>James Homans, Melissa Lee, Alda Huang</i>
33.2 Antifungal Therapy 1647 <i>Arunaloke Chakrabarti, Prashant Sood</i>	33.7 Blastomycosis 1672 <i>G Raghurama Rao</i>
33.3 Candidiasis 1652 <i>Kheya Ghosh Uttam</i>	33.8 Histoplasmosis 1675 <i>S Nivedhana, S Balasubramanian</i>
33.4 Aspergillosis 1657 <i>Kana Ram Jat</i>	33.9 Pneumocystis jirovecii (Previously Classified as P. carinii) 1678 <i>Ira Shah, Noella Maria Delia Pereira</i>
33.5 Cryptococcosis 1661 <i>Ankit Parakh</i>	33.10 Pediatric Mucormycosis 1681 <i>Dhanya Dharmapalan, Rajeev Soman</i>

SECTION 34**RICKETTSIAL AND OTHER INFECTIONS**Section Editor: **S Balasubramanian**

34.1 Epidemiology, Classification, and Approach to Diagnosis of Rickettsial Infections 1685 <i>Narendra Rath</i>	34.5 Murine Typhus (Flea-borne or Endemic Typhus) 1697 <i>Govind Benakatti, LH Bidari</i>
34.2 Spotted Fevers 1688 <i>Atul A Kulkarni</i>	34.6 Mycoplasma Infections 1699 <i>Tanu Singhal</i>
34.3 Scrub Typhus 1693 <i>Veena R Parmar</i>	34.7 Chlamydial Infections 1702 <i>Sulochana Putli Bai</i>
34.4 Epidemic Typhus 1695 <i>Sunil Vaidya, Atul A Kulkarni</i>	

PART VIII**SYSTEMIC PEDIATRICS****SECTION 35****DIARRHEAL ILLNESSES**Section Editor: **AK Patwari**

35.1 Acute Watery Diarrhea 1707 <i>AK Patwari</i>	35.4 Persistent Diarrhea 1723 <i>Shinjini Bhatnagar, Aashima Dabas, Dheeraj Shah</i>
35.2 Dysentery 1714 <i>AKM Iqbal Kabir, Lazina Sharmin</i>	35.5 Chronic Diarrhea 1729 <i>Babu Lal Meena, Bijaylaxmi Behera, (LATE) BR Thapa</i>
35.3 Cholera 1718 <i>Piyush Gupta, Swati Kalra</i>	35.6 Antibiotic-associated Diarrhea 1749 <i>Seema Alam, Vikrant Sood</i>

SECTION 36

GASTROINTESTINAL DISORDERS

Section Editors: **A Riyaz, John Matthai**

36.1 Anatomy and Physiology	1754	36.14 Hirschsprung Disease	1808
<i>S Arivu Selvan</i>		<i>Ketan Parikh</i>	
36.2 Common Symptoms of Gastrointestinal Diseases	1759	36.15 Malabsorption Disorders	1810
<i>Sarah Paul, John Matthai</i>		<i>Vyom Aggarwal</i>	
36.3 Dental Caries	1762	36.16 Celiac Disease	1819
<i>Madhu S</i>		<i>Ujjal Poddar</i>	
36.4 Cleft Lip and Cleft Palate	1767	36.17 Inflammatory Bowel Disease	1824
<i>VS Akbar Sherif, Sayed Mohammed Akbar</i>		<i>Rishi Bolia, Anshu Srivastava</i>	
36.5 Diseases of Salivary Glands	1772	36.18 Intestinal Obstruction	1832
<i>Prakash Agarwal</i>		<i>Ketan Parikh</i>	
36.6 Vomiting	1775	36.19 Intussusception	1835
<i>Sumathi Bavanandam</i>		<i>Ketan Parikh</i>	
36.7 Disorders of Esophageal Motility	1779	36.20 Appendicitis	1838
<i>Rohan Malik</i>		<i>Prakash Agarwal</i>	
36.8 Gastroesophageal Reflux	1783	36.21 Abdominal Tuberculosis	1840
<i>Uma Padhye Phatak, Dinesh S Pashankar</i>		<i>Rajesh Kumar Meena, Sanghamitra Ray</i>	
36.9 Infantile Hypertrophic Pyloric Stenosis and Other Congenital Anomalies of the Stomach	1786	36.22 Ascites	1844
<i>Ketan Parikh</i>		<i>Malathi Sathiyasekaran, R Ganesh</i>	
36.10 Functional Abdominal Pain	1789	36.23 Umbilical Hernia	1849
<i>B Bhaskar Raju, Sumathi Bavanandam</i>		<i>Prakash Agarwal</i>	
36.11 Acid Peptic Disease	1793	36.24 Inguinal Hernia	1851
<i>R Bhanu Vikraman Pillai</i>		<i>Prakash Agarwal</i>	
36.12 Pancreatitis and Pancreatic Tumors	1797	36.25 Testicular Torsion	1853
<i>A Riyaz, Geeta M Govindaraj</i>		<i>Prakash Agarwal</i>	
36.13 Constipation	1803	36.26 Anorectal Disorders	1855
<i>Praveen Kumar, Preeti Singh</i>		<i>Ajay Narayan Gangopadhyay, Vaibhav Pandey</i>	

SECTION 37

HEPATOBIILIARY DISEASES

Section Editor: **Surender Kumar Yachha**

37.1 Applied Anatomy and Physiology of Liver and Biliary Tract	1861	37.7 Acute Hepatitis	1906
<i>Vishnu Biradar</i>		<i>Barath Jagadisan</i>	
37.2 Liver Function Tests	1864	37.8 Chronic Liver Disease	1909
<i>Neelam Mohan, Sakshi Karkra</i>		<i>Seema Alam, Rajeev Khanna</i>	
37.3 Neonatal Cholestasis	1870	37.9 Hepatic Encephalopathy	1930
<i>Surender Kumar Yachha, Moinak Sen Sarma</i>		<i>Moinak Sen Sarma, Surender Kumar Yachha</i>	
37.4 Portal Hypertension	1880	37.10 Acute Liver Failure	1938
<i>Surender Kumar Yachha, Moinak Sen Sarma</i>		<i>Karunesh Kumar, Smita Malhotra, Anupam Sibal</i>	
37.5 Gastrointestinal Bleeding	1894	37.11 Liver Tumors	1942
<i>Nishant Wadhwa, Jaswinder Kaur</i>		<i>Vimal Kumar, Naresh P Shanmugam</i>	
37.6 Liver Abscess	1901		
<i>Upender Shava, Anshu Srivastava</i>			

SECTION 38

DISORDERS OF HEMATOPOIETIC SYSTEM

Section Editor: **VP Choudhry**

38.1 The Hematopoietic System 1948	38.13 Red Blood Cell Enzyme Defects 2035
<i>Shruti Kakkar, Praveen C Sobti, Vikram Narang</i>	<i>Manoranjan Mahapatra</i>
38.2 Approach to Diagnosis of Anemia 1957	38.14 Immune Hemolytic Anemia 2039
<i>MR Lokeshwar, Swati Kanakia, Asha Pillai, Swati Gupta</i>	<i>Nita Radhakrishnan, Anupam Sachdeva</i>
38.3 Anemia: Etiology and Classification 1974	38.15 Physiology of Hemostasis 2044
<i>Nitin Shah, Sunil Udgire</i>	<i>Renu Saxena, Neha Singh, Udayakumar DS</i>
38.4 Congenital Bone Marrow Failure 1978	38.16 Bleeding and Coagulation Disorders 2050
<i>Maitreyee Bhattacharya, Meet Kumar, Sukrita Bhattacharjee</i>	<i>Tulika Seth</i>
38.5 Aplastic Anemia 1985	38.17 Hemophilia 2056
<i>Amita Mahajan</i>	<i>Pravas Mishra, Nivedita Dhingra</i>
38.6 Iron Deficiency Anemia 1989	38.18 Other Clotting Factor Deficiencies 2064
<i>Mamta Manglani, VP Choudhry</i>	<i>Arun Danewa</i>
38.7 Megaloblastic Anemia 1996	38.19 Thrombocytopenia 2067
<i>Sangeeta Mudaliar, Bharat Agarwal</i>	<i>Amita Trehan, Sidharth Totadri</i>
38.8 Approach to Hemolytic Anemia 2002	38.20 Immune Thrombocytopenia 2074
<i>VP Choudhry</i>	<i>Jagdish Chandra, Puneet Kaur Sahi</i>
38.9 Hemoglobinopathies 2009	38.21 Platelet Function Defects 2084
<i>HP Pati, Deepti Mutreja</i>	<i>Neelam Varma</i>
38.10 Sickle Cell Disease 2013	38.22 Thrombotic Disorders 2088
<i>Dipty Jain, Vibhavari Dani, Roshan Colah</i>	<i>Sidharth Totadri, Deepak Bansal</i>
38.11 Thalassemia 2021	38.23 Disseminated Intravascular Coagulation 2097
<i>VP Choudhry, JS Arora</i>	<i>VK Khanna, Divij Sachdeva, Manas Kalra, Anupam Sachdeva</i>
38.12 RBC Membrane Defects 2031	38.24 Blood Component Therapy 2102
<i>Nitin Shah, Khushnuma Mullanfiroze</i>	<i>Anupam Verma, Hemlata, Nabajyoti Choudhury</i>

SECTION 39

RESPIRATORY DISEASES

Section Editors: **Varinder Singh, SK Kabra**

39.1 Anatomy and Physiology of Respiration 2107	39.9 Sinusitis 2149
<i>Pankaj C Vaidya</i>	<i>SD Subba Rao</i>
39.2 Approach to Diagnosis of a Respiratory Disorder 2116	39.10 Tonsils and Adenoids 2154
<i>Varinder Singh</i>	<i>Pallab Chatterjee</i>
39.3 Congenital Malformations of the Upper Respiratory Tract 2120	39.11 Obstructive Sleep Apnea 2158
<i>D Vijayasekaran</i>	<i>Zeynep Seda Uyan, Refika Ersu</i>
39.4 Epistaxis 2124	39.12 Congenital Malformations of the Lower Respiratory Tract 2163
<i>Jagdish Chinnappa, Deepa Shivnani</i>	<i>D Vijayasekaran</i>
39.5 Allergic Rhinitis 2128	39.13 Stridor and Croup 2168
<i>Ankit Parakh, Varinder Singh</i>	<i>Shalu Gupta</i>
39.6 Otitis Media 2133	39.14 Approach to a Child with Fast Breathing 2173
<i>Jagdish Chinnappa, Deepa Shivnani</i>	<i>Varinder Singh</i>
39.7 Approach to a Child with Cough 2140	39.15 Approach to a Child with Wheeze 2175
<i>Subramanya NK, Vidya K</i>	<i>Varinder Singh</i>
39.8 Common Cold and Acute Pharyngitis 2143	39.16 Bronchiolitis 2177
<i>Satnam Kaur</i>	<i>Ilin Kinimi, Supriya Shinde</i>

39.17 Alpha-1 Antitrypsin Deficiency	2183	39.25 Interstitial Lung Disease	2219
<i>Kana Ram Jat, Rakesh Lodha, SK Kabra</i>		<i>A Bush</i>	
39.18 Aspiration Syndromes	2184	39.26 Hemoptysis and Alveolar Bleeds	2225
<i>Mahesh Babu Ramamurthy, Michael Lim Teik Chung</i>		<i>Meenu Singh, Nandini Paul, Manvi Singh</i>	
39.19 Preschool Wheeze and Bronchial Asthma	2188	39.27 Primary Ciliary Dyskinesia	2229
<i>KR Bharath Kumar Reddy, Samatha Sonnappa</i>		<i>Ada YF Yip, Eric YT Chan, Daniel KK Ng</i>	
39.20 Aerosol Therapy	2199	39.28 Cystic Fibrosis	2233
<i>Bruce K Rubin, Ronald W Williams</i>		<i>SK Kabra, Kana Ram Jat, Rakesh Lodha</i>	
39.21 Pneumonia	2202	39.29 Bronchiectasis	2238
<i>Swati Dubish, Varinder Singh</i>		<i>Lokesh Guglani</i>	
39.22 Parapneumonic Effusion and Empyema	2209	39.30 Lung Abscess	2243
<i>Kamal Kumar Singhal</i>		<i>Kana Ram Jat, Meghna Sharma</i>	
39.23 Pneumothorax and Air Leaks	2213	39.31 Tracheobronchial Foreign Body Aspiration	2245
<i>Mandeep Walia, Abhishek Somasekhara Aradhya</i>		<i>Varinder Singh, Ankit Parakh</i>	
39.24 Persistent and Recurrent Pneumonia	2216	39.32 Central Hypoventilation	2247
<i>Ankit Parakh, Varinder Singh</i>		<i>Mahesh Babu Ramamurthy, Daniel YT Goh</i>	

SECTION 40

CARDIOVASCULAR DISORDERS

Section Editors: **S Srinivasan, M Zulfikar Ahamed**

40.1 Historical Aspects and Advances in Pediatric Cardiology	2250	40.15 Patent Ductus Arteriosus	2333
<i>S Srinivasan</i>		<i>K Sivakumar</i>	
40.2 Development of the Heart	2252	40.16 Anomalous Left Coronary Artery from Pulmonary Artery, Coronary Arterial Fistula, and Ruptured Sinus of Valsalva	2337
<i>S Srinivasan</i>		<i>MS Ranjith, Sakshi Sachdeva</i>	
40.3 Fetal Circulation	2257	40.17 Pulmonary Stenosis	2339
<i>Munesh Tomar, Savitri Shrivastava</i>		<i>Shreepal Jain, Bharat Dalvi</i>	
40.4 Cardiovascular Examination	2262	40.18 Coarctation of Aorta	2344
<i>M Zulfikar Ahamed</i>		<i>Kshitij Sheth, Bharat Dalvi</i>	
40.5 Genetics in Heart Diseases	2267	40.19 Aortic Stenosis	2349
<i>Sumaira Khalil, Seema Kapoor</i>		<i>Smita Mishra</i>	
40.6 Chest Skiagram in Heart Disease	2273	40.20 Approach to Infants and Children with Cyanotic Heart Disease	2355
<i>BRJ Kannan</i>		<i>M Zulfikar Ahamed</i>	
40.7 Electrocardiogram	2279	40.21 Tetralogy of Fallot and Variants	2360
<i>BRJ Kannan</i>		<i>Anita Saxena, Mrigank Choubey</i>	
40.8 Echocardiography	2288	40.22 Tricuspid Atresia	2368
<i>Balu Vaidyanathan</i>		<i>P Syamasundar Rao</i>	
40.9 Cardiac Catheterization and Other Advanced Imaging Methods	2293	40.23 Transposition of Great Arteries	2377
<i>Duraisamy Balaguru</i>		<i>R Suresh Kumar, Navaneetha Sasikumar</i>	
40.10 Congestive Heart Failure	2299	40.24 Truncus Arteriosus	2380
<i>Parvathi U Iyer, Nilanjan Dutta, Kuntal Roy Chowdhuri</i>		<i>Duraisamy Balaguru</i>	
40.11 Cardiac Malpositions	2309	40.25 Ebstein Anomaly, Pulmonary Arteriovenous Fistula, Corrected Transposition of Great Arteries	2383
<i>P Syamasundar Rao</i>		<i>Sunita Maheshwari</i>	
40.12 Ventricular Septal Defects	2319	40.26 Admixture Lesions	2386
<i>IB Vijayalakshmi</i>		<i>Neeraj Awasthy, S Radhakrishnan</i>	
40.13 Atrial Septal Defects	2324	40.27 Hypoplastic Left Heart Syndrome	2392
<i>K Sivakumar</i>		<i>Joseph John Vettukattil</i>	
40.14 Atrioventricular Septal Defects	2330		
<i>Snehal Kulkarni, Tanuja Karande</i>			

40.28 Pulmonary Arterial Hypertension 2395 <i>Sakshi Sachdeva, Nageswara Rao Koneti</i>	40.34 Diseases of the Pericardium 2438 <i>Manoj Kumar Rohit, Navjyot Kaur</i>
40.29 Acute Rheumatic Fever 2402 <i>B Anjaiah</i>	40.35 Cardiac Dysrhythmias 2441 <i>Ramandeep S Ahuja, (Late) Rajnish Juneja</i>
40.30 Rheumatic Heart Disease and Lesions of the Mitral Valve 2409 <i>R Krishna Kumar</i>	40.36 Systemic Disorders with Heart Disease 2461 <i>Anita Khalil</i>
40.31 Rheumatic Aortic Valve Disease 2416 <i>Savitri Shrivastava, Sakshi Sachdeva</i>	40.37 Cardiac Emergencies 2465 <i>Umesh Dyamenahalli</i>
40.32 Infective Endocarditis 2419 <i>Shakuntala Prabhu, Sumitra Venkatesh</i>	40.38 Surgical Considerations in Congenital Heart Diseases 2470 <i>R Benedict Raj, S Srinivasan</i>
40.33 Myocardial Diseases: Myocarditis and Cardiomyopathies 2427 <i>Ronak Naik, Nishant Shah</i>	40.39 Preventive Cardiology in the Young 2474 <i>S Sivasankaran</i>

VOLUME 3

Systemic Pediatrics, Pediatric Subspecialties, and Social Pediatrics

SECTION 41

DISORDERS OF THE KIDNEY AND URINARY TRACT

Section Editors: **Arvind Bagga, Aditi Sinha**

41.1 Anatomy and Physiology 2481 <i>Priyanka Khandelwal, Arvind Bagga</i>	41.12 Acute Kidney Injury 2527 <i>Anil Vasudevan</i>
41.2 Investigations for Kidneys and Urinary Tract 2485 <i>Susan Uthup, Jyoti Sharma</i>	41.13 Renal Replacement Therapy 2533 <i>Sidharth Kumar Sethi, Rupesh Raina</i>
41.3 Congenital Anomalies of Kidneys and Urinary Tract 2490 <i>Shilpa Sharma, Aditi Sinha</i>	41.14 Hemolytic Uremic Syndrome 2535 <i>Aditi Sinha, Arvind Bagga</i>
41.4 Cystic Kidney Diseases 2497 <i>Shina Menon</i>	41.15 Renal Tubular Acidosis 2539 <i>Arvind Bagga, Aditi Sinha</i>
41.5 Enuresis 2500 <i>Girish C Bhatt, Piyush Gupta</i>	41.16 Tubular Disorders 2544 <i>Kamran Afzal</i>
41.6 Hematuria 2505 <i>Rajiv Sinha</i>	41.17 Renal Calculi 2549 <i>Indira Agarwal</i>
41.7 Glomerulonephritis 2507 <i>Amarjeet Mehta, Arvind Bagga, Shina Menon, Manisha Sahay</i>	41.18 Refractory Rickets 2553 <i>Abhijeet Saha</i>
41.8 Systemic Vasculitis and Lupus Nephritis 2512 <i>Ashima Gulati, Arvind Bagga</i>	41.19 Hypertension 2556 <i>Swasti Chaturvedi</i>
41.9 Alport Syndrome and Related Disorders 2516 <i>Mukta Mantan</i>	41.20 Urinary Tract Infection and Vesicoureteric Reflux 2561 <i>Pankaj Hari</i>
41.10 Proteinuria 2518 <i>Sushmita Banerjee</i>	41.21 Voiding Disorders 2568 <i>Madhuri Kanitkar, Suprita Kalra</i>
41.11 Nephrotic Syndrome 2520 <i>Arvind Bagga, Aditi Sinha</i>	41.22 Chronic Kidney Disease 2572 <i>Erica Winnicki, Lavjay Butani, Stephanie Nguyen</i>
	41.23 End-stage Kidney Disease 2575 <i>Celina Brunson, Asha Moudgil</i>

SECTION 42

NEUROLOGICAL DISORDERS

Section Editors: **S Aneja, Suvasini Sharma**

42.1 Approach to Neurological Disorders 2579	42.16 Viral Encephalitis 2675
<i>Suvasini Sharma, S Aneja</i>	<i>Mary Iype</i>
42.2 Cerebrospinal Fluid and Neurophysiology 2585	42.17 Neurocysticercosis 2682
<i>Anita Choudhary, Jyotindra Narayan Goswami</i>	<i>Pratibha Singhi</i>
42.3 Neuroimaging 2593	42.18 Brain Abscess 2687
<i>Atin Kumar, Jyoti Kumar</i>	<i>Prashant Jauhari, Jitendra Kumar Sahu</i>
42.4 Neural Tube Defects and Spinal Cord Malformations 2604	42.19 Coma, Raised Intracranial Pressure, and Brain Death 2693
<i>Sujata Kanhere</i>	<i>Gurpreet Singh Kochar, Suvasini Sharma</i>
42.5 Microcephaly 2611	42.20 Pseudotumor Cerebri 2703
<i>Jaya Shankar Kaushik</i>	<i>Anaita Udwadia-Hegde, Omkar P Hajirnis</i>
42.6 Brain Malformations 2619	42.21 Stroke 2705
<i>Jatinder S Goraya</i>	<i>Ramesh Konanki, Pradhya Gadgil</i>
42.7 Hydrocephalus 2624	42.22 Movement Disorders 2715
<i>Daljit Singh, Hukum Singh</i>	<i>Debabrata Ghosh</i>
42.8 Febrile Seizures 2629	42.23 Ataxia 2725
<i>Sangeetha Yoganathan</i>	<i>Rahul Ojha, Asuri N Prasad</i>
42.9 Seizures and Epilepsy 2632	42.24 Infantile Tremor Syndrome 2732
<i>Puneet Jain, Lakshminarayanan Kannan</i>	<i>Jatinder S Goraya, Sukhjot Kaur</i>
42.10 Treatment of Seizures and Epilepsy 2642	42.25 Inflammatory Demyelinating Disorders 2736
<i>Gopinath Musuwadi Subramanian</i>	<i>Rachel Sze Hui Wong, Bindu Parayil Sankaran</i>
42.11 Status Epilepticus 2647	42.26 Autoimmune and Paraneoplastic Encephalitis and Encephalopathies 2744
<i>Kaajal Parbhoo, Puneet Jain</i>	<i>Lokesh Lingappa, Sirisharani Siddaiahgari</i>
42.12 Nonepileptic Paroxysmal Disorders 2653	42.27 Neurocutaneous Disorders 2749
<i>Hema Patel, David W Dunn</i>	<i>Maya Thomas, Renu George, Karthik Muthusamy</i>
42.13 Headache 2658	42.28 Neurometabolic Disorders 2757
<i>Devendra Mishra</i>	<i>Mahesh Kamate</i>
42.14 Acute Bacterial Meningitis 2664	42.29 Neurodegenerative Disorders 2763
<i>Lokesh Saini, Shivan Kesavan</i>	<i>Naveen Sankhyan</i>
42.15 Tuberculosis of the Central Nervous System 2669	42.30 Spinal Cord Disorders 2773
<i>Chandrakanta, Rashmi Kumar</i>	<i>Vyunkunta Raju KN</i>

SECTION 43

NEUROMUSCULAR DISORDERS

Section Editors: **Sheffali Gulati, J Andoni Urtizberea**

43.1 Approach to Diagnosis of Neuromuscular Disorders 2779	43.6 Muscular Dystrophies 2816
<i>Sheffali Gulati, Jaya Shankar Kaushik, J Andoni Urtizberea, MC Sharma</i>	<i>Satish V Khadilkar, Rakhil S Yadav</i>
43.2 Floppy Infant 2793	43.7 Congenital Muscular Dystrophy 2827
<i>Anaita Udwadia-Hegde, Shilpa Kulkarni</i>	<i>Sunil Pradhan, AK Meena</i>
43.3 Acute Flaccid Paralysis 2800	43.8 Congenital Myopathies 2840
<i>Biswaroop Chakrabarty, Sheffali Gulati</i>	<i>Kimberly Amburgey, Michael W Lawlor, James J Dowling</i>
43.4 Guillain-Barré Syndrome 2805	43.9 Neuromuscular Transmission Disorders 2845
<i>Vrajesh Udani</i>	<i>Venkateswaran Ramesh</i>
43.5 Spinal Muscular Atrophy 2809	43.10 Hereditary Motor and Sensory Neuropathies 2850
<i>Soumya Sundaram, Sruthi S Nair, Muralidharan Nair</i>	<i>Viswanathan V</i>
	43.11 Autonomic Neuropathies 2854
	<i>Rachana Dubey, Ashok Jaryal, Sachendra Badal, Sheffali Gulati</i>

SECTION 44

DISORDERS OF THE ENDOCRINE GLANDS

Section Editors: **PSN Menon, Vijayalakshmi Bhatia**

44.1 Principles of Endocrinology and Hormone Action	2864	44.17 Cushing Syndrome.....	2930
<i>Khalid Hussain</i>		<i>Maha Elhassan, Michael A Wood</i>	
44.2 Introduction to Neuroendocrinology	2868	44.18 Endocrine Hypertension	2936
<i>Priyanka Gupta, Vijayalakshmi Bhatia</i>		<i>Praveen VP</i>	
44.3 Growth Hormone Deficiency and Resistance	2871	44.19 Glucocorticoid Use and Withdrawal	2942
<i>Arpita K Vyas, Ram K Menon</i>		<i>VK Bhardwaj</i>	
44.4 Polyuria, Diabetes Insipidus, and Syndrome of Inappropriate Secretion of ADH	2878	44.20 Disorders of Sex Development	2944
<i>Tushar Godbole, PSN Menon</i>		<i>Ganesh S Jevalikar, Sapna Nayak, Preeti Dabadghao</i>	
44.5 Thyroid Hormone Physiology	2882	44.21 Cryptorchidism and Micropenis	2954
<i>Anna Simon</i>		<i>Aparna Limaye</i>	
44.6 Hypothyroidism and Thyroiditis	2884	44.22 Classification of Diabetes Mellitus	2957
<i>Palany Raghupathy</i>		<i>Aspi Irani</i>	
44.7 Newborn Screening for Congenital Hypothyroidism	2889	44.23 Type 1 Diabetes Mellitus	2961
<i>Anna Simon</i>		<i>Aspi Irani</i>	
44.8 Hyperthyroidism	2891	44.24 Acute and Chronic Complications of Diabetes Mellitus	2969
<i>Sobha Kumar</i>		<i>KG Ravikumar</i>	
44.9 Goiter and Thyroid Nodules	2894	44.25 Bone Mineral and Hormone Physiology	2974
<i>Lalitha Kailas, Riaz I</i>		<i>Philip G Murray, M Zulf Mughal</i>	
44.10 Normal Puberty	2897	44.26 Calcium Disorders	2976
<i>Ruchi Parikh, Meena Desai</i>		<i>Shaila Sukthankar, Raja Padidela</i>	
44.11 Delayed Puberty	2902	44.27 Metabolic Rickets.....	2980
<i>Vijaya Sarathi, Nalini S Shah</i>		<i>Shaila Sukthankar, Raja Padidela</i>	
44.12 Precocious Puberty	2906	44.28 Disorders with Bone Fragility	2983
<i>Prisca Colaco</i>		<i>M Zulf Mughal</i>	
44.13 Gynecomastia	2912	44.29 Genetic Obesity	2987
<i>Anju Virmani</i>		<i>Leena Priyambada</i>	
44.14 Normal Development and Physiology of the Adrenal Gland	2915	44.30 Hyperlipidemia.....	2993
<i>Rajesh Joshi</i>		<i>Nisha Bhavani</i>	
44.15 Congenital Adrenal Hyperplasia.....	2918	44.31 Endocrine Consequences of Thalassemia Major....	2997
<i>Anurag Bajpai, PSN Menon</i>		<i>Archana Dayal Arya</i>	
44.16 Adrenal Insufficiency and Polyglandular Syndromes	2924	44.32 Endocrine Effects of Radiation and Cancer Chemotherapy	3000
<i>M Vijayakumar</i>		<i>Margaret Zacharin</i>	
		44.33 Adult Consequences of IUGR and Preterm Birth	3003
		<i>Sarah Mathai, Paul Hofman</i>	

SECTION 45

PEDIATRIC MALIGNANCIES

Section Editor: **Deepak Bansal**

45.1 Epidemiology of Cancers in Children	3006	45.4 Acute Myeloid Leukemia	3024
<i>Ramandeep Singh Arora</i>		<i>Akash Nahar, Yaddanapudi Ravindranath</i>	
45.2 Principles of Therapy of Cancer in Children	3012	45.5 Chronic Myelogenous Leukemia	3030
<i>Gaurav Kharya, Neeraj Teotia, Prashant Jain, Shikha Haldar</i>		<i>Arathi Srinivasan, Julius Xavier Scott</i>	
45.3 Acute Lymphoblastic Leukemia	3018	45.6 Myelodysplastic Syndrome and Juvenile Myelomonocytic Leukemia.....	3036
<i>Revathi Raj, Deenadayalan M</i>		<i>Sangeeta Mudaliar, Archana Swami</i>	

45.7 Hodgkin Lymphoma	3041	45.12 Retinoblastoma	3083
<i>Maharshi Trivedi, Vishal Sondhi</i>		<i>Anirban Das, Deepak Bansal</i>	
45.8 Non-Hodgkin Lymphoma	3047	45.13 Soft Tissue Tumors	3093
<i>Vikramjit S Kanwar, Tipu Nazeer, Maharshi Trivedi</i>		<i>Sandeep Jain, Gauri Kapoor</i>	
45.9 Brain Tumors	3055	45.14 Bone Tumors	3098
<i>Anaita Udwadia-Hegde, Omkar P Hajirnis, Girish Chinnaswamy</i>		<i>Ashish Gulia, Tushar Vora</i>	
45.10 Neuroblastoma	3070	45.15 Histiocytic Disorders	3103
<i>Maya Prasad, Purna Kurkure</i>		<i>Gaurav Narula, Nirmalya D Pradhan</i>	
45.11 Wilms Tumor	3076	45.16 Oncological Emergencies and Supportive Care	3110
<i>Sajid Shafique Qureshi</i>		<i>Anand Prakash, ATK Rau</i>	
		45.17 Hematopoietic Stem Cell Transplant	3119
		<i>Satyendra Katewa, Satya Prakash Yadav</i>	

SECTION 46

RHEUMATOLOGICAL DISORDERS

Section Editor: **Anju Gupta**

46.1 Approach to Rheumatological Disorders	3128	46.7 Juvenile Dermatomyositis	3168
<i>Anand Prahalad Rao</i>		<i>Priyanka Pal</i>	
46.2 Laboratory Investigations for Rheumatological Disorders	3133	46.8 Large Vessel Vasculitis: Takayasu Arteritis	3174
<i>Anju Gupta, Tapas Kumar Sabui</i>		<i>Anju Gupta</i>	
46.3 Drugs and Principles of Management for Rheumatic Disorders	3141	46.9 Medium Vessel Vasculitis: Kawasaki Disease and Polyarteritis Nodosa	3179
<i>Narendra Kumar Bagri</i>		<i>Sikha Agarwal, Surjit Singh</i>	
46.4 Juvenile Idiopathic Arthritis	3147	46.10 Small Vessel Vasculitis: IgA Vasculitis and ANCA-associated Vasculitis	3183
<i>Sujata Sawhney</i>		<i>Nutan Kamath, Neelakshi Ghosh, Rakesh Mondal</i>	
46.5 Systemic Lupus Erythematosus: Clinical Features and Diagnostic Criteria	3155	46.11 Juvenile Scleroderma	3191
<i>Sathish Kumar T, Anu Punnen</i>		<i>Suma Balan</i>	
46.6 Management of Systemic Lupus Erythematosus	3163	46.12 Antiphospholipid Syndrome	3195
<i>Aruna Bhat</i>		<i>Jasmina Ahluwalia, Anju Gupta</i>	
		46.13 Systemic Autoinflammatory Disorders	3198
		<i>Madhumita Nandi, Sumantra Sarkar</i>	

PART IX

PEDIATRICS SUBSPECIALTIES

SECTION 47

COMMON EYE ABNORMALITIES

Section Editor: **Kirti Singh**

47.1 Common Visual Problems	3205	47.5 Uveitis	3232
<i>Kirti Singh</i>		<i>SR Rathinam, R Vedhanayaki</i>	
47.2 Congenital Anomalies of Eye	3209	47.6 Cataract and Lens	3239
<i>Saumika Singh, Sima Das</i>		<i>Abhay R Vasavada, Vaishali Vasavada</i>	
47.3 Refractive Errors	3219	47.7 Glaucoma in Children	3247
<i>Kirti Singh, Divya Jain</i>		<i>Kirti Singh, Arshi Singh, Mainak Bhattacharyya</i>	
47.4 Cornea and Conjunctiva	3227	47.8 Optic Nerve and Pupil	3256
<i>Ritu Arora, Aditi Manudhane</i>		<i>Digvijay Singh, Pradeep Sharma</i>	

47.9 Strabismus and Motility Disorders 3261	47.12 Ocular Manifestations of Systemic Disorders 3283
<i>AK Amitava, Shivani Grover</i>	<i>Koushik Tripathy, Pradeep Venkatesh</i>
47.10 Eyelid, Orbit, and Lacrimal Sac 3272	47.13 Visually Impaired Child 3293
<i>Apjit Kaur</i>	<i>Kirti Singh, Mainak Bhattacharyya, Arshi Singh</i>
47.11 Ocular Injuries 3278	
<i>Kalpana Narendran, Sandra C Ganesh, Murali Krishnan S</i>	

SECTION 48**COMMON SKIN PROBLEMS**Section Editor: **Sandipan Dhar**

48.1 Skin of the Newborn: Physiological and Pathological Changes 3300	48.10 Cutaneous Manifestations of Nutritional Deficiency 3360
<i>Keshavmurthy A Adya, Arun C Inamadar</i>	<i>Vibhu Mendiratta</i>
48.2 Care of Skin in the Newborn 3308	48.11 Cutaneous Manifestations of Collagen Vascular Diseases 3364
<i>S Sacchidanand, Preeti Sheth</i>	<i>Yogesh S Marfatia</i>
48.3 Infections and Infestations 3311	48.12 Neurocutaneous Syndromes 3368
<i>S Criton, Sruthi Mohanan</i>	<i>Resham J Vasani</i>
48.4 Congenital Cutaneous Malformations 3319	48.13 Vesiculobullous Disorders 3374
<i>Manish K Shah</i>	<i>Rashmi Sarkar, Shanthi Devadasan, Bhawna Wadhwa</i>
48.5 Vitiligo and Other Hypopigmentary Diseases 3322	48.14 Papulosquamous Diseases 3377
<i>Tarun Narang, Hitaishi Mehta</i>	<i>Ravi Hiremagalore, Subhash Lokre, Priya Bishnoi</i>
48.6 Atopic Dermatitis 3331	48.15 Ichthyosis 3384
<i>Deepak A Parikh, Abhijit Saha</i>	<i>Deepika Pandhi, Ankita Chauhan</i>
48.7 Contact Dermatitis 3333	48.16 Genetic Cutaneous Disorders 3391
<i>Raghbir Banerjee, Sandipan Dhar</i>	<i>Manjot Manish Gautam, Vedant Madhav Ghuse</i>
48.8 Urticaria and Mastocytosis 3334	48.17 Hair Disorders 3395
<i>Deepika Pandhi, Priyesh Thakran</i>	<i>Tarang Goyal, Sakshi Kohli</i>
48.9 Cutaneous Drug Reactions 3342	
<i>Vishal Gaurav, Chander Grover</i>	

SECTION 49**DISORDERS OF BONES AND JOINTS**Section Editor: **Harish S Hosalkar**

49.1 Assessment of the Locomotor System 3400	49.7 Legg-Calve-Perthes Disease 3430
<i>Jayanth Sundar Sampath, Harish S Hosalkar</i>	<i>Venkatadass K, Harish S Hosalkar</i>
49.2 Osteomyelitis 3405	49.8 Osgood-Schlatter Disease 3434
<i>Darshan Kapoor, Mandar V Agashe, Harish S Hosalkar</i>	<i>Joana Manuel Ferreira Freitas, Harish S Hosalkar</i>
49.3 Septic Arthritis 3408	49.9 Congenital Talipes Equinovarus 3436
<i>Darshan Kapoor, Mandar V Agashe, Harish S Hosalkar</i>	<i>Darshan Kapoor, Mandar V Agashe, Harish S Hosalkar</i>
49.4 Neck Problems 3411	49.10 Skeletal Dysplasias 3439
<i>Vijay HD Kamath, Harish S Hosalkar</i>	<i>Kuldeep Singh, Varuna Vyas, Abhay Elhence</i>
49.5 Scoliosis and Kyphosis 3418	49.11 Arthrogyposis 3458
<i>Vijay HD Kamath, Harish S Hosalkar</i>	<i>Jayanth Sundar Sampath, Harish S Hosalkar</i>
49.6 Developmental Dysplasia of the Hip 3426	
<i>Venkatadass K, Harish S Hosalkar</i>	

PART X

SOCIAL PEDIATRICS

SECTION 50

VULNERABLE CHILDREN

Section Editor: **Sanjay Chaturvedi**

50.1 Vulnerability	3463	50.4 Child Abuse and Neglect	3476
<i>Dheeraj Shah, Piyush Gupta</i>		<i>Kiran Aggarwal</i>	
50.2 Street Children	3465	50.5 Adoption: Medical and Legal Issues	3486
<i>Pranab Chatterjee, Sanjay Chaturvedi</i>		<i>Samir H Dalwai</i>	
50.3 Child Labor	3469	50.6 Rights of the Child	3490
<i>Swati Ghate, Utkarsh Bansal</i>		<i>Swati Y Bhawe, Piyush Gupta</i>	

SECTION 51

COMMUNITY PEDIATRICS

Section Editor: **Piyush Gupta**

51.1 Indicators of Child Health	3494	51.5 Programs for Child Health	3512
<i>Piyush Gupta, Dhulika Dhingra</i>		<i>Amir Maroof Khan, Piyush Gupta,</i>	
51.2 Screen Time and Media in Children	3501	<i>Shyambhavee Behera</i>	
<i>Nidhi Bedi, Dheeraj Shah, Piyush Gupta</i>		51.6 Integrated Management of Neonatal	
51.3 Environment and Child Health	3504	and Childhood Illness	3520
<i>Dhulika Dhingra, Piyush Gupta</i>		<i>AK Patwari</i>	
51.4 Lead Poisoning	3510		
<i>Dhulika Dhingra, Piyush Gupta</i>			

PART XI

ANNEXURES

LABORATORY VALUES AND DRUG FORMULARY

Section Editor: **Pooja Dewan**

Annexure A: Laboratory Reference Values	3573	Annexure B: Pediatric Drug Formulary	3583
<i>Nidhi Bedi, Pooja Dewan</i>		<i>Pooja Dewan, Nidhi Bedi</i>	

Index	I-1-I-00
--------------------	-----------------



Chief Editor
Piyush Gupta

Prof. Piyush Gupta

List of Supplementary Videos from the Course Available on DigiNerve



Login and Subscribe to View

Section 1 Introduction to Pediatrics

Video 1: Steps of conducting research the ABC (RQ, Aim, Objectives)—
Piyush Gupta

Video 2: Study designs—*Dheeraj Shah*

Video 3: Sample size estimation—*Amir Maroof Khan*

Video 4: Principles of statistical analysis—*Amir Maroof Khan*

Video 5: Resources for learning in pediatrics—*Dheeraj Shah*

Section 2 Genetics and Genetic Disorders

Video 1: Approach to diagnosis of genetic disorders—*Madhulika Kabra*

Video 2: Chromosomal disorders (introduction)—*Shubha R Phadke*

Video 3: Chromosomal disorders—*Ratna Dua Puri*

Section 3 Metabolic Disorders

Video 1: Approach to diagnosis of inborn errors of metabolism—
Neeraj Gupta

Video 2: Newborn screening in India—*Seema Kapoor*

Section 4 Immunity, Immune Disorders, and Allergy

Video 1: Approach to primary immunodeficiency diseases—*Praveen Kumar*

Section 5 Fluid and Electrolytes

Video 1: Fluid therapy—*Vikram Bhaskar*

Video 2: ABC of ABG—*Shalu Gupta*

Video 3: Electrolyte abnormalities in critically ill children—*M Jayashree*

Section 7 Acutely Ill Child and Resuscitation

Video 1: Cardiopulmonary resuscitation—*Shalu Gupta*

Section 8 Intensive Care

Video 1: Shock—*Jhuma Sankar*

Video 2: Oxygen therapy and ventilation—*Nitin Dhochak, Rakesh Lodha*

Section 12 Normal Newborn

Video 1: Neonatal resuscitation—*Ashish Jain*

Video 2: Assessment of gestational age—*Shashi Kant Dhir*

Video 3: Neonatal reflexes: A demonstration—*Shashi Kant Dhir*

Video 4: Breastfeeding and human milk banking—*Sushma Nangia*

Section 14 High-risk Newborn

Video 1: X-ray and ECG in neonates—*Praveen Kumar*

Video 2: Neonatal jaundice—*Ashok Kumar*

Video 3: Follow-up of high-risk newborn—*Naveen Jain*

Section 16 Neurological Problems

Video 1: HIE, IVH and white matter injury—*Shiv Sajjan Saini*

Section 18 Malformations

Video 1: Comprehensive newborn screening for birth defects—*Arun Singh*

Section 19 Growth: Normal and Abnormal

Video 1: Growth and growth charts—*Anju Seth*

Video 2: Approach to short stature—*Sirisha Kusuma B*

Section 20 Development and Developmental Delay

Video 1: Principles of developmental evaluation—

Sharmila Banerjee Mukherjee

Video 2: Developmental assessment first 6 months of life—*Vishal Sondhi*

Video 3: Developmental examination (6 months–2 years)—

Biswaroop Chakrabarty

Video 4: Developmental examination (2–5 years)—*Prashant Jauhari*

Video 5: Case scenarios in developmental deviations—*Lokesh Saini*

Video 6: How to present a case of cerebral palsy?—*Jaya Shankar Kaushik*

Section 22 Nutrition and Nutritional Disorders

Video 1: Nutritional status of children and national programs in India—
Piyush Gupta

Video 2: Assessment of nutritional status (basics and dietary assessment)—*Praveen Kumar*

Video 3: Assessment of nutritional status (anthropometric measurement)—*Praveen Kumar*

Video 4: Complementary feeding—*Praveen Kumar*

Video 5: Severe acute malnutrition: Part I—*Praveen Kumar*

Video 6: Severe acute malnutrition: Part II—*Praveen Kumar*

Video 7: Micronutrient supplementation: Key issues—*Dheeraj Shah*

Video 8: JUNGCS guidelines and way forward—*Piyush Gupta*

Section 23 Immunization

Video 1: Immunization dialogue I (immunization schedules vaccines, AEFI, case-scenarios, FAQ)—*Ashok Kumar Dutta, Piyush Gupta*

Video 2: Immunization dialogue II (immunization schedules vaccines, AEFI, case-scenarios, FAQ)—*Ashok Kumar Dutta, Piyush Gupta*

Section 27 Basic Concepts in Infectious Diseases

Video 1: Antimicrobial resistance—*Sushil Kabra*

Video 2: Prevention of hospital-acquired infections—*Banani Poddar*

Section 29 Bacterial Infections

Video 1: Principles of antibiotic therapy—*Amarjeet Chitkara*

Video 2: Resistant bacterial infections—*Shyam Kukreja*

Section 30 Mycobacterial Infections

Video 1: Diagnosis of tuberculosis—*Varinder Singh*

Video 2: Treatment of tuberculosis—*Varinder Singh*

Section 31 Viral Diseases

Video 1: Antiviral therapy—*Valsan Verghese*

Video 2: COVID-19—*S Balasubramanian*

Section 32 Protozoal Infections and Infestations

Video 1: Helminthiasis: Current perspectives—*Piyush Gupta*

Section 35 Diarrheal Illnesses

Video 1: Persistent diarrhea—*Dheeraj Shah*

Section 36 Gastrointestinal Disorders

Video 1: Examination of abdomen—*Piyush Gupta*

Video 2: Approach to a child with hepatosplenomegaly—*K Rajeshwari*

Video 3: Approach to a child with constipation—*Rajesh Kumar Meena*

Video 4: Approach to a child with malabsorption—*Dheeraj Shah*

Section 37 Hepatobiliary Diseases

Video 1: Approach to a child with jaundice—*Seema Alam*

Video 2: Interpretation of liver function tests—*Moinak Sen Sarma*

Video 3: Upper GI bleed: Diagnosis and management—*Anuradha Rai*

Video 4: Portal hypertension and ascites—*Anuradha Rai*

Video 5: Approach to chronic liver disease—*Malathi Sathiyasekaran*

Section 38 Disorders of Hematopoietic System

Video 1: Approach to a child with hepatosplenomegaly—*K Rajeshwari*

Video 2: Approach to a child with anemia (Part 1)—

Deepak Bansal, Srinivasan Peyam

Video 3: Approach to a child with anemia (Part 2)—

Deepak Bansal, Srinivasan Peyam

Video 4: Nutritional anemia—*Shruti Kakkar*

Video 5: Hemolytic anemia: Thalassemia—*Vineeta Gupta*

Video 6: Bleeding disorders in pediatric practice—*Nita Radhakrishnan*

Video 7: Approach to coagulation disorders—*Sidharth Totadri*

Section 39 Respiratory Diseases

Video 1: Examination of respiratory system—*Kana Ram Jat*

Video 2: Aerosol therapy—*Jagdish Goyal*

Video 3: Bronchial asthma: Acute management—*Somu Sivabalan*

Video 4: Bronchial asthma: Long-term management—*Ankit Parakh*

Video 5: Pneumonia: Differential diagnosis and management—

Joseph L Mathew

Video 6: Pleural effusion: A case-based discussion—

Rashmi Ranjan Das

Section 40 Cardiovascular Disorders

Video 1: Examination of cardiovascular system in children—

Srikanta Basu

Video 2: ECG and arrhythmias in children—*Raghavan Nair Suresh Kumar*

Video 3: Approach to a child with congenital heart disease—

Munesh Tomar

Video 4: Approach to cyanotic heart diseases—*Saileela Rajan*

Video 5: Left-to-right shunts—*Saurabh Gupta*

Video 6: Cyanotic heart disease (Fallot physiology)—*M Zulfikar Ahamed*

Video 7: Pediatric pulmonary hypertension—*Prashant Bhopate*

Video 8: Rheumatic fever and rheumatic heart disease—*Anita Saxena*

Video 9: Cardiomyopathies and congestive heart failure (Part 1)—

Sweta Mohanty

Video 10: Cardiomyopathies and congestive heart failure (Part 2)—

Sweta Mohanty

Section 41 Disorders of the Kidney and Urinary Tract

Video 1: Urinary tract infection—*Manish Kumar*

Video 2: Hypertension—*Jyoti Sharma*

Video 3: Approach to hematuria and acute nephritic syndrome—

Kirti Sudha Sen

Video 4: Proteinuria and nephrotic syndrome—*OP Mishra*

Video 5: Acute kidney injury—*Abhijeet Saha*

Video 6: Chronic kidney disease—*Mukta Mantan*

Video 7: Renal tubular disorders—*Kanika Kapoor*

Section 42 Neurological Disorders

Video 1: Clinical neuroanatomy—*Jaya Shankar Kaushik*

Video 2: Higher mental function assessment—*Jaya Shankar Kaushik*

Video 3: Cranial nerve examination—*Jaya Shankar Kaushik*

Video 4: Examination of the motor system part I: Gait, tone, and muscle bulk (examination of gait and muscle bulk tone)—

Jaya Shankar Kaushik

Video 5: Examination of the motor system part II: Muscle power—

Jaya Shankar Kaushik

Video 6: Examination of sensory system, cerebellar and meningeal signs—*Jaya Shankar Kaushik*

Video 7: Case-based understanding of localization in neurology—

Divyani Garg

Video 8: How to summarize and present a neurological case—

Jaya Shankar Kaushik

Video 9: Bare basics of interpreting neuroimaging—*Atin Kumar*

Video 10: Understanding the basics of EEG—*Suvasini Sharma*

Video 11: Case-based approach to hydrocephalus and neural tube defects—*Ranjith Kumar Manokaran*

Video 12: Case-based discussion of seizure and epilepsy in children—

Sheffali Gulati

Video 13: Common case scenarios presenting with epilepsy in children—

Rekha Mittal

Video 14: Case presentation of TBM—*Jaya Shankar Kaushik*

Video 15: Pediatric stroke: Challenges in diagnoses and management—

Lokesh Lingappa

Video 16: Movement disorders: Phenotypic/clinical spectrum—

Vishal Sondhi

Section 43 Neuromuscular Disorders

Video 1: Approach to floppy infant—*Shivan Kesavan*

Video 2: Case presentation of DMD—*Jaya Shankar Kaushik*

Section 44 Disorders of the Endocrine Glands

Video 1: Interpretation of thyroid function tests in newborn—

Ganesh S Jevalikar

Video 2: Congenital hypothyroidism: Differential diagnosis and management—

Sophy Korula

Video 3: Diabetes type 1: Ambulatory management—*M Vijayakumar*

Video 4: Diabetic ketoacidosis—*KG Ravikumar*

Video 5: Approach to early puberty—*Abraham Paulose*

Video 6: Approach to delayed puberty—*Vijaya Sarathi*

Video 7: Disorders of sex development: A practical approach—

Vijayalakshmi Bhatia

Section 46 Rheumatological Disorders

Video 1: Approach to a child with rheumatic disorder and pGALS examination—*Suma Balan*

Video 2: Rational diagnostics for rheumatic disorders: Laboratory investigations—*Narendra Kumar Bagri*

Video 3: Rational diagnostics for rheumatic disorders: Imaging—

Manisha Jana

Video 4: Principles of management of pediatric rheumatological disorders—*Vignesh P*

Video 5: Juvenile idiopathic arthritis and mimics—*Narendra Kumar Bagri*

Video 6: Childhood-onset systemic lupus erythematosus (cSLE)—

Narendra Kumar Bagri

Video 7: Approach to pediatric vasculitis—*Sathish Kumar T*

Video 8: Macrophage activation syndrome—*Narendra Kumar Bagri*

Video 7: Approach to pediatric vasculitis—*Sathish Kumar T*

Video 8: Macrophage activation syndrome—*Narendra Kumar Bagri*

Section 49 Disorders of Bones and Joints

Video 1: Approach to skeletal dysplasia—*Girisha Katta*

Section 51 Community Pediatrics

Video 1: Indicators of child health and vital statistics—*Piyush Gupta*

Kumar R, Tripathi P, Singh S, et al. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. *Clinical Infect Dis*. 2006;43(2):123-31.

Lu SJ, Goh PS. Isolated temporal lobe involvement in Japanese encephalitis. *J Neuroimaging*. 2009;19(3):280-2.

Solomon T, Nguyen Minh Dung, Kneen R, et al. Japanese encephalitis. *J Neurol Neurosurg Psychiatry*. 2000;68:405-15.

Solomon T. Recent advances in Japanese encephalitis. *J Neurovirology*. 2003;9(2):274-83.

Swami R, Ratho RK, Mishra B, et al. Usefulness of RT-PCR for the diagnosis of Japanese encephalitis in clinical samples. *Scandinavian J Infect Dis*. 2008;40(10):815-20.

World Health Organization. (2007). WHO Manual for the Laboratory Diagnosis of Japanese Encephalitis Virus Infection. [Online] Available from https://www.who.int/immunization/monitoring_surveillance/burden/laboratory/Manual_lab_diagnosis_JE.pdf?ua=1 [Last accessed October, 2021].

World Health Organization. Japanese encephalitis vaccines. *Wkly Epidemiol Rec*. 2006;81(34/35):331-40.

31.19

Dengue

Piyush Gupta, Aashima Dabas

Dengue infection results in an acute febrile illness, caused by four closely related virus serotypes of the genus *Flavivirus*, family *Flaviviridae*. Dengue virus is transmitted to humans mainly by the *Aedes aegypti* mosquito. The disease is characterized by a biphasic fever, and may be associated with hemorrhagic manifestations. In 10–20% cases, the patient develops shock because of plasma leakage into the third space. Worldwide, children younger than 15 years comprise 90% of patients with dengue fever. Dengue is one of the 20 diseases listed by the World Health Organization (WHO) under their 2021–2030 roadmap against Neglected Tropical Diseases (NTDs).

CLINICAL SPECTRUM

Dengue virus infection may be asymptomatic, lead to a benign illness, or present with severe manifestations. The WHO in 1997 classified symptomatic dengue virus infections in the following groups:

- Undifferentiated dengue fever
- *Dengue fever*: Defined as presence of fever of 2–7 days duration with any two of the following—myalgia, retro-orbital pain, headache, rash, and arthralgia
- *Dengue hemorrhagic fever* (DHF): A patient is classified as DHF if following four criteria are met: (1) fever or history of fever in last 2–7 days; (2) bleeding tendencies—positive tourniquet test, petechiae, purpura, mucosal bleeds; (3) thrombocytopenia—platelet count $<100,000/\text{mm}^3$; and (4) hemoconcentration [defined as $>20\%$ rise in hematocrit (Hct)] or evidence of plasma leakage—pleural effusion, ascites or hypoproteinemia. The DHF was further graded in four stages (**Box 1**).
- *Dengue shock syndrome* (DSS). All of the above criteria plus hypotension.

Later, it was realized that this classification was at times difficult to apply in clinical settings, was not able to categorize all patients with dengue, and was missing out cases with severe dengue. Also, dengue fever and DHF may not be continuum of same disease and may exist as separate clinical conditions. The WHO thus proposed a new classification for severity of dengue fever in 2009.

The WHO classification in 2009 had three severity categories—(1) dengue fever; (2) dengue fever with *warning signs*; and (3) severe dengue (**Fig. 1**). It is important to note that children without warning signs can also develop severe dengue.



BOX 1: Grading of dengue hemorrhagic fever (WHO, 1997).

Grade I: Fever, nonspecific complaints, positive tourniquet test, and no spontaneous bleeds
Grade II: Spontaneous bleeds in addition to signs and symptoms of grade I
Grade III: Circulatory failure—cold clammy extremities and hypotension
Grade IV: Profound shock

- *Nonsevere manifestations* consist of a biphasic fever, generalized body ache, rash, and a positive *tourniquet test*. These may or may not be associated with warning signs.
- *Warning signs* should be detected by close observation of the patient, so as to institute early and aggressive therapy. These include—(1) abdominal pain or tenderness, (2) persistent vomiting, (3) clinical fluid accumulation (edema, pleural effusion, and ascites), (4) mucosal bleeds, (5) hepatomegaly by >2 cm, and (6) hemoconcentration as evidenced by increasing Hct with concomitant and rapid fall in platelet count.
- *Severe manifestations* include—(1) severe hemorrhage, (2) profound shock, and (3) multisystem involvement. Presence of any one of these three criteria is sufficient for making a diagnosis of severe dengue infection.

Expanded dengue syndrome is a term introduced in 2011, which refers to unusual and severe involvement of the liver, kidney, brain, or heart in association with dengue.

National Vector-borne Disease Control Program Nomenclature

Recently, the National Vector Borne Disease Control Program (NVB-DCP) has accepted the revised WHO classification for dengue as shown in **Flowchart 1**. There may be asymptomatic subjects who may be tested positive for dengue. Among symptomatic patients, they can be classified into three categories—mild, moderate, and severe dengue.

GEOGRAPHICAL DISTRIBUTION

Global

Dengue fever is known in the tropical Southeast Asia and Western Pacific for more than a century. The hemorrhagic form was first recognized in Philippines in 1953. Subsequently, DHF was recognized in Thailand, India, Malaysia, Singapore, and Vietnam. In 1978, a big outbreak was reported from China resulting in 22,122 cases. In 1981, a large epidemic occurred in Cuba resulting in nearly 0.35 million cases of dengue fever. Out of these, 24,000 had DHF and 10,000 had DSS. Dengue has also been noticed in temperate regions of North America, Africa, and Mediterranean Europe.

As per current estimates, at least 100 countries are endemic for DHF and about 40% of the world populations (2.5 billion people) are at risk in tropics and subtropics. In 2010, 1.6 million cases of dengue were reported in the Americas alone, of which 49,000 cases were severe dengue. Recently, dengue has also been reported from Costa Rica, Mexico, France, Croatia, and Portugal. Incidence of dengue infections annually has almost doubled from 50 million to 96 million (2010) in last few years. A recent meta-analysis on data




Fig. 1: Suggested dengue case classification and levels of severity.

(Hct: hematocrit; DSS: dengue shock syndrome; AST: aspartate transaminase; ALT: alanine transaminase; CNS: central nervous system)

Source: Reproduced with permission of the publisher from: Dengue, Guidelines for Treatment, Prevention Control. Geneva: WHO; 2009.

from 84 articles from 21 countries in sub-Saharan Africa showed an increase in the prevalence of IgM dengue antibodies suggesting that 10–14% population developed acute dengue infection in last 10 years and 25% of the population had elevated IgG suggesting history of exposure to dengue at some point in time. The pooled dengue virus RNA prevalence was 14% (95% CI: 12–16%), which reflected the poor vector control strategy in sub-Saharan Africa.

India

India alone accounted for almost 34% of global dengue burden by 2010. The National Dengue Day was observed on 16th May 2016. Disease is prevalent throughout India in most of the metropolitan cities and towns and is endemic in 18 out of 35 states. Outbreaks have also been reported from rural areas of Haryana, Maharashtra, and Karnataka. Recent trends in transmission have shown occurrence of larger and more frequent outbreaks, geographic expansion of endemic transmission, spread of the disease from urban to periurban and rural areas, and an increasing proportion of severe cases and deaths. An increased propensity to hyperendemicity, particularly in large urban areas, is also noted.

During 1996, a severe outbreak of dengue or DHF occurred in Delhi wherein about 10,252 cases and 423 deaths were reported. In 2006, India witnessed another outbreak with 12,317 cases and 184 deaths in 21 states. The initial epidemics in India were due to serotype 2 or 4. The dengue serotype 1 was seen as predominant serotype in Delhi during 2007–2010. Concurrent infection of chikungunya and dengue serotype 2 has been reported from Vellore and Delhi. Cyclic epidemics are increasing in frequency and in-country geographic expansion is reported in India due to deciduous dry and wet climatic zone with circulation of multiple virus serotypes. However, with improved case management, the case fatality has decreased from 3.3% in 1996 to 0.4% in 2010.

ETIOLOGY

Dengue virus (DENV) has at least four serotypes (1, 2, 3, and 4). These are antigenically very similar, but do not offer a complete cross-protection after infection by either one of them. Infections in human

by a serotype will produce lifelong immunity against reinfection by the same serotype. Subsequent infection (secondary infection) by another serotype results in severe dengue. The severity of epidemics caused by serotype 1 has been reported to be maximum followed by types 2 and 3. Recent report from northwest India reported DENV-2 as the most common serotype with maximum proportion of severe cases. However, DENV-4 remains the most common serotype in circulation in Karnataka followed by DENV-2 and DENV-3. Coinfection with more than one serotype was seen in <10% cases.


EPIDEMIOLOGY

Vector

Aedes aegypti is the vector for dengue virus. Female mosquito bites the man during daytime. After feeding on a person with viremia, the female mosquito can transmit dengue immediately or after a period of 10–14 days (*extrinsic incubation period*). The extrinsic incubation period is a critical factor in successful transmission of the disease. A lower environmental temperature increases the extrinsic incubation period, which in turn, decreases the transmission. Once the mosquito becomes infective, it remains so till it dies.

The flight range of an adult *A. aegypti* mosquito is not >25–50 m in an urban environment. However, the vector can be transported by water, land, and air travel contributing to the transmission. For dengue transmission, the number of infected female mosquitoes per house is important. Usually this number is small, and, in an Indian epidemic, it was observed to be just 1 per household (*house index*). The minimum vector density, below which the dengue transmission ceases, is not known. The *A. aegypti* mosquito breeding is not necessarily related to the ambient temperature. The mosquito has been found at altitudes as high as 2,200 m above the sea level. Vectors must survive longer than the sum of the initial nonfeeding period after birth (usually 2 days) and the extrinsic incubation period to be able to infect another human. Longevity under natural conditions ranges from 8 days to 42 days. The eggs of *A. aegypti* can survive without water for a year.

An increase in resistance to commonly used insecticides is reported among *Aedes* from Southeast Asia. The common mechanisms of insecticide resistance include the following—(1) resistance of the target

Flowchart 1: Classification of dengue—WHO, 2015.

*Close monitoring: Hct, Plt, Hb, fluid intake/output, HR, RR, BP consciousness.

(DF: dengue fever; DHF: dengue hemorrhagic fever; CAD: coronary artery disease; DSS: dengue shock syndrome; Hct: hematocrit; Plt: platelet; Hb: hemoglobin; HR: heart rate, RR: respiratory rate; BP: blood pressure)

Source: National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. (2014). National guidelines for clinical management of dengue fever. [Online] Available from <https://nvbdcp.gov.in/Doc/Dengue-National-Guidelines-2014.pdf> [Last accessed October, 2021].

site of insecticidal action in mosquitoes through genetic modification, (2) metabolic resistance where resistant strains can detoxify or metabolize the insecticides, (3) penetration resistance to the insecticides through outer cuticle of mosquitoes, and (4) behavioral adaptation where mosquitoes develop mechanisms to evade contact with insecticides.

Host

People at all ages are susceptible to dengue. In Asians, disease is more severe in children. This is in contrast to America where infection mainly occurs in adults, which is generally mild. Severe dengue occurs at high frequency in (1) infants and (2) children having experienced a previous dengue infection. Other factors associated with increase

host susceptibilities to severe disease include bronchial asthma; human immunodeficiency virus (HIV); certain human leukocyte antigen (HLA) types—HLA I (A04, A24, B0, B46), HLA II (DR1, DR4, DQ); polymorphisms in tumor necrosis factor-alpha (TNF- α); transforming growth factor-beta (TGF- β); vitamin D receptors; glucose-6-phosphate dehydrogenase deficiency, and mutations in mannose-binding lectin-2 gene.

Environmental Factors

In many tropical countries, a positive association between rainfall or larval density and dengue incidence has been documented. The vector survives best at temperature 16–30°C and humidity of 60–80%.

However, dengue epidemics have also been recorded in those areas where rainfall is unusually low. The transmission occurs only if the ambient temperature is above 16°C. Therefore, the transmission tends to decline when winter approaches. This is due to prolongation of extrinsic incubation period beyond the longevity of mosquito.

Transmission Risk Factors

When a member of a household is infected with dengue, other family members are at risk. Dengue spread is facilitated in any vector infested place where people congregate, such as schools, temples, cinema halls, offices, hospitals, factories, etc. In urban areas, the movement of infected people accounts for spread of virus than the movement of *Aedes* mosquito.

In Utero Transmission

Dengue infection of pregnant women may result in passive transfer of antidengue immunoglobulin G (IgG) to the fetus or a congenital infection. These infants with maternal antibody are at a higher risk of developing severe dengue and many develop DHF during primary exposure.

■ PATHOGENESIS

Dengue virus infects the peripheral blood mononuclear cells within a few days of infective mosquito bite. Two patterns of immune response follow—(1) *primary* and (2) *secondary (anamnestic)*. Persons never previously infected with a flavivirus, nor immunized with a flavivirus vaccine (e.g., yellow fever, Japanese encephalitis), mount a primary IgM antibody response when infected with dengue virus, appearing within 2–3 days of defervescence and peaking at 2 weeks after the onset of symptoms. Antidengue IgG appears afterward. Individuals with immunity due to previous flavivirus infection or immunization mount a secondary (anamnestic) antibody response when infected with dengue virus. In secondary flavivirus infections, which account for most cases of severe dengue, the dominant immunoglobulin is IgG; the levels of IgM being much lower. A mechanism of immune enhancement or antibody dependent enhancement (ADE) is observed in dengue due to heterologous non-neutralizing antibodies. This is responsible for serious organ dysfunction and hemorrhagic disturbances, which can occur during secondary infection by a different serotype. This mechanism promotes binding of dengue virus to surface expressed Fc gamma (Fc_γ) receptors on monocytes and macrophages, further promoting viral replication and spread. Thus, sequential rather than simultaneous exposure of different serotypes of dengue virus carry a higher chance of ADE resulting in serious disease. Thus, antibody against a strain of dengue virus does not protect from a different strain of virus. Rather, it may increase its capacity to multiply in human monocytes. The infected monocytes result in activation of cross-reactive CD4⁺ and CD8⁺ cytotoxic lymphocytes. Cytotoxic lymphocytes mediate release of cytokines resulting in plasma leakage and hemorrhage and are primarily responsible for host defense in dengue mediated via interferon-gamma. Recent studies have highlighted the role of HLA-linked protective role of CD8 lymphocytes. Researchers have found that certain phenotypes of HLA may cause hyporesponsiveness of interferon- γ response, thereby weakening the host response.

■ PATHOPHYSIOLOGY

Two main pathophysiological changes occur in dengue. These are—(1) *increased vascular permeability*, resulting in loss of plasma from the vascular compartment, hemoconcentration, low pulse pressure, and other signs of shock; and (2) disorder in the hemostasis involving thrombocytopenia, vascular changes, and coagulopathy.

Secondary dengue infection results in formation of immune complexes and activation of complement system. TNF- α , interferon,

and interleukin-2 are elevated, and C1q, C3–C8, are depressed. As a result, vasoactive amines are released from the platelets. These cause massive release of water, electrolytes, and plasma proteins from the blood vessels and lead to hypovolemic shock.

Increased vascular permeability is mediated through the nitric oxide pathway.

Platelet defects are both quantitative and qualitative. Thus, a patient with a normal platelet count may still have a prolonged bleeding time. Maculopapular and petechial rashes are present. In these lesions, dengue antigen, IgM, and complement (C3) have been observed.

It may be noted that virus is usually not detectable in blood once shock manifests, though viral replication occurs in various organs.

■ CLINICAL FEATURES

Dengue infections have a wide clinical presentation. Following an incubation period of 3–7 days, the illness is characterized by three distinct phases—(1) febrile phase, (2) critical phase, and (3) phase of recovery.

Febrile Phase

This phase is characterized by a high-grade fever up to 104°F, abrupt in onset. Fever remains at the peak for 48–72 hours before it starts declining. It is accompanied with nonspecific constitutional symptoms, such as generalized myalgia, body ache, anorexia, nausea, vomiting, and headache. Parents may notice an erythematous rash, especially over the extremities. Infants with dengue usually have fever accompanied with gastrointestinal or nonspecific respiratory symptoms. There may be flushing of skin with compromised cutaneous circulation (**Fig. 2**). Some children may have associated sore throat, or arthralgia. These features, by themselves, are however not sufficient enough to arrive at a diagnosis of dengue fever. Dengue should be strongly suspected, if above features are associated with mild hemorrhagic manifestations including petechial hemorrhages, mucosal bleeds, or a positive tourniquet test. Presence of tender hepatomegaly (without obvious icterus) strongly favors possibility of dengue infection. The febrile phase lasts for 2–3 days.

Complications

High fever in this phase can cause dehydration, febrile delirium, and febrile seizures in children <5 years of age. Febrile seizures, respiratory, and gastrointestinal manifestations are common in infants with dengue. Hepatomegaly is more frequently found in infants than in older children.

Critical Phase

Onset of the critical phase is closely linked to the time of defervescence that occurs by third day of illness. All children in defervescence phase need to be closely monitored for the *warning signs* as described earlier. Those manifesting with one or more of these signs are likely to enter the critical phase. Not all children with dengue infection enter



Fig. 2: Cutaneous flushing of forearm with blanching on applying pressure.

this phase. Many children improve progressively after defervescence (nonsevere dengue).

Critical phase is characterized by an increase in capillary permeability. This is preceded by a fall in the platelet count. Increased capillary permeability results in leakage of plasma into the third space. Clinically, this manifests as polyserositis, i.e., pleural effusion and ascites. Plasma leakage from the intravascular compartment into the third space results in hemoconcentration in the vascular bed, reflected by a rising Hct. Increase in Hct is directly proportional to the volume of plasma lost from the vascular compartment.

Epigastric discomfort, tenderness at right costal margin, and generalized abdominal pain are common. Liver becomes palpable. Petechiae may be present over extremities, axillae, face, and palate. Studies from India have reported the most frequent symptoms as fever, abdominal pain, headache, and vomiting.

Leakage of a significant volume of plasma leads to hypovolemia, hypoperfusion, and shock. Hypoperfusion may result in multiple end-organ impairment, metabolic acidosis, and disseminated intravascular coagulation (DIC). Consumption coagulopathy results in hemorrhage that may cause a fall in Hct. End-organ impairment manifests with hepatitis, myocarditis, or encephalitis. Children developing profound shock, severe hemorrhage, or multisystem involvement are at higher risk of mortality, and thus are said to be having *severe dengue infection*. These children need aggressive management. This phase lasts for 48 hours.

Recovery Phase (Plasma Reabsorption Phase)

Plasma starts coming back to the intravascular compartment, provided the patient survives the critical phase of plasma leakage and shock. Onset of this phase is characterized by an improvement in general well-being and appetite. Urine output improves and pain abdomen subsides. Though this is the phase of improvement, child should be monitored carefully for hypervolemia. Reabsorption of leaked plasma plus administration of excess intravenous (IV) fluid may result in fluid overload, pulmonary edema, and congestive heart failure, manifesting as dyspnea, tachycardia, and raised jugular venous pressure. Cardiovascular manifestations (bradycardia and arrhythmias) are also reported during this phase. Hct value either normalizes or may show a decline below normal. Platelet count starts improving. This phase lasts for 48–72 hours. Thus, most patients with dengue fever run a typical course of disease lasting from 7 to 10 days (Fig. 3).




Fig. 3: The course of dengue illness. (Ig: immunoglobulin)

Source: Reproduced with permission of the publisher from Dengue, Guidelines for Treatment, Prevention Control. Geneva: WHO; 2009.

Severe Dengue

Children and adolescents with severe dengue have a more protracted course and recovery may take 10–14 days. Dengue shock is characterized by a narrow pulse pressure ≤ 20 mm Hg, cold extremities, delayed capillary refill time, weak pulse, and tachycardia. Skin becomes cool, blotchy, and congested. Typically, consciousness is not altered. Major bleeding can occur from gastrointestinal tract or brain. Organ impairment manifests as hepatic failure, renal failure, myocarditis, or encephalopathy. Atypical manifestations include acute inflammatory colitis, uveitis, myositis, Guillain-Barré syndrome, and Kawasaki disease.

Neurological manifestations are increasingly being reported in dengue infection commonly with DENV-2 and DENV-3 serotypes with an incidence varying from 0.5 to 21%. The neurological manifestations can result from direct virus-mediated action (neurotropism), postinfectious immune-mediated reaction or associated metabolic derangements in dengue infection. The spectrum of neurological manifestations varies from encephalopathy, encephalitis, aseptic meningitis, meningoencephalitis, stroke (hemorrhagic or ischemic stroke), acute disseminated encephalomyelitis, ataxia, Guillain-Barré syndrome, transverse myelitis, and myopathy. Dengue encephalopathy may be commonly associated with severe dengue or dengue shock syndrome, or with other metabolic abnormalities. Analysis of cerebrospinal fluid becomes important in suspected cases with neurological involvement in endemic areas. The leukocyte count in CSF may be normal in dengue encephalitis; however, it may yield positive results on immunoassays (specific IgM) and molecular tests (RT-PCR) to identify DENV and exclude other possible infectious causes. Neuroimaging may be normal or may show nonspecific changes in encephalitis, meningoencephalitis, and myelitis. Peripheral nervous system involvement is less frequently seen than central nervous system and usually presents later in the course of disease.

Notably, epidemiological studies have not found any correlation between platelet count and occurrence of bleeding manifestations or risk of mortality. The risk factors for mortality reported from adult studies include shock, hepatitis, renal failure, encephalopathy, and plasma leakage.

DIAGNOSIS

Hematological Tests

The clinical diagnosis is corroborated by raised Hct and thrombocytopenia:

- An Hct level rise of $>20\%$ is a sign of hemoconcentration and precedes shock. The Hct level should be monitored at least every 24 hours to facilitate early recognition of *warning signs* and every 3–4 hours in *severe dengue*.
- Thrombocytopenia occurs in up to 50% of children with dengue. Platelet counts of $<100,000$ cells/ μL indicate onset of *critical phase* and typically occur before defervescence and the onset of shock. The platelet count should be monitored at least every 24 hours initially.
- The white blood cell count can be normal or show leukocytosis during initial phase. Leukopenia, often with lymphopenia, precedes thrombocytopenia and is observed near the end of the febrile phase of illness.

Biochemical Profile

Prothrombin time is prolonged. Activated partial thromboplastin time is prolonged. Low fibrinogen and elevated fibrin degradation product levels are signs of DIC. Hyponatremia is the most common electrolyte abnormality in critical phase. Metabolic acidosis and elevated blood urea are observed in those with shock. Serum glutamic pyruvic transaminase (SGPT) levels are elevated. Low serum albumin levels are a sign of hemoconcentration.

TABLE 1: Diagnostic tests for dengue fever.

Diagnostic method	Timing of test (after disease onset)	Validity
Virus isolation (culture)	1–5 days	++++
Genome detection (PCR)	1–5 days	++++
Antigen detection (NS1)	1–5 days	+++
Antibody detection (IgM)	After 5 days*	++
IgG (paired sera)**	Acute sera 1–5 days; convalescent sera after 15 days	+

*IgM positivity rates: by 3–5 days (50%), 5–7 days (80%), and 10 days (90%). IgM appears between 3 and 10 days and disappears by 2–3 months.

**IgG appears after 1–2 weeks and may persist for life.

(PCR: polymerase chain reaction; Ig: immunoglobulin)

Serodiagnosis

Serum specimens should be sent to the laboratory for serodiagnosis, polymerase chain reaction (PCR), and viral isolation. Because the signs and symptoms of dengue fever are nonspecific, attempting laboratory confirmation of dengue infection is important. Serodiagnosis is based on—(1) detection of viral nonstructural protein 1 (NS1) during initial illness; (2) detection of IgM antibodies to dengue; or (3) fourfold rise in dengue IgG in paired samples. **Table 1** outlines the desired timing of these tests for confirming the diagnosis. Laboratory criteria for definitive diagnosis include one or more of the following:

- Isolation of the dengue virus from serum, plasma, leukocytes, or autopsy samples
- Demonstration of dengue virus antigen in serum samples via enzyme immunoassay or in autopsy tissue via immunohistochemistry or immunofluorescence can be done. NS1 is a glycoprotein produced by the virus, which can be detected early, between 1st and 4th day of illness. It is specific and has a high sensitivity.
- Demonstration of a fourfold or greater change in reciprocal IgG or IgM antibody titers to one or more dengue virus antigens in paired serum samples. IgM antibody appears early in disease course, requires single sample, and is less cross-reactive to other flaviviruses. Thus, measurement of raised IgM appears to be most prudent when done after 5th day of illness. As per the NVBDCP, the laboratory test being followed is the IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) for dengue virus, which captures the dengue-specific IgM by using antihuman IgM. There are quicker and cheaper rapid diagnostic test (RDT) kits available, which test the presence of anti-IgM or IgG or NS1 antigen. However, these kits carry a high false-positive rate and are not recommended by the WHO or under NVBDCP.
- Detection of viral genomic sequences in autopsy tissue, serum, or cerebral spinal fluid (CSF) samples via PCR.

Diagnostic kits for NS1 and MAC-ELISA can be procured from National Institute of Virology, Pune under NVBDCP. The Government of India has set up surveillance hospitals and apex referral laboratories for improved disease surveillance.

TREATMENT Dengue Fever

The mainstay of treatment is supportive therapy. Increased oral fluid intake is recommended to prevent dehydration. Supplementation with IV fluids may be necessary to prevent dehydration and significant hemoconcentration. Fever is managed with paracetamol. Aspirin and nonsteroidal anti-inflammatory drugs should be avoided as these drugs may worsen the bleeding tendency associated with some of these infections. Shock is managed with isotonic fluids. Packed cell transfusion is indicated in refractory shock or if there is significant bleeding.

Patients with known or suspected dengue fever should have their platelet count and Hct measured daily from the third day of illness until 1–2 days after defervescence. Patients with a rising Hct level or falling platelet

count should be monitored more frequently. Management of dengue illness can be discussed in three steps:

Step 1: Overall assessment

Step 2: Diagnosis and severity assessment

Step 3: Categorizing into mild, moderate or severe dengue and treating accordingly

Overall Assessment

History and Examination

Emphasis on history should be on assessment of *warning signs*. Physical examination should concentrate on hemodynamic assessment, so as to determine the presence and extent of shock, confirming or detecting the warning signs, and checking for bleeding manifestations, abdominal tenderness, mental state, and hydration. Tourniquet test is a must.

Investigations

Initial investigations should include an Hct, WBC count, platelet count, and tests to confirm the diagnosis, as described in the section on laboratory diagnosis. In critical phase, additional tests need to be done and include liver function test, renal function test, chest X-ray, serum electrolytes, and ultrasound abdomen.

Diagnosis and Severity Assessment

Determine the phase of disease (febrile, critical, and recovery) and severity (nonsevere, severe) of dengue, as per criteria outlined earlier. The child will need admission if any of the following criteria is fulfilled:

- Presence of any of warning signs
- Signs and symptoms of hypotension
- Bleeding from any site
- Renal, hepatic, or central nervous system (CNS) involvement
- Pleural effusion or ascites
- Rising Hct
- Platelet count $<50,000/\text{mm}^3$
- High-risk age group—infants and old age

Categorize Patients in Mild, Moderate, and Severe Dengue (Table 2)

This step is aimed to place the patient in an appropriate group (mild, moderate, and severe) to decide on future course of action, as follows:

- Mild:* Patients, who may be sent home
- Moderate:* Patients needing close monitoring and hospitalization
- Severe:* Patients requiring tertiary level care

Mild Dengue: Home Management

All children who are tolerating oral fluids, passing urine at least once in 6 hours, and not having any of the warning signs can be sent home. Following management needs to be advised:

- Encourage fluid intake; can give oral rehydration salt (ORS), fruit juice, etc. The parents should be advised to increase the amount of oral fluids to be given (e.g., 3–10 kg: 100 mL/kg and 10–20 kg: 75 mL/kg)
- Paracetamol (15 mg/kg/dose) if the child is uncomfortable because of fever. Avoid aspirin, ibuprofen, mefenamic acid, and nimesulide.
- Monitor at home for fluid intake, urine output, fever, obvious bleeding, and altered sensorium.
- Bring back if any of the above is present or the child develops any of the warning signs.

Parents of infants should be explained the danger signs before discharging them home. Tepid sponging for fever should be done as febrile convulsions may occur commonly in this age group. Breastfeeding should be encouraged and continued.

TABLE 2: Treatment of dengue.

Category	Patient characteristics	Treatment
Mild	Accepting orally, passing urine adequately and no warning signs*	Home therapy: Increased oral fluids, paracetamol
Moderate	<ul style="list-style-type: none"> Warning signs* present High risk-infants, old age, pregnancy Comorbid conditions** 	Hospitalize: <ul style="list-style-type: none"> Monitor hematocrit, platelets, vitals Intravenous fluids: Titrated as per hematocrit If worsens, manage as severe dengue
Severe	<ul style="list-style-type: none"> Severe bleeding Severe shock Severe organ dysfunction: Hepatic, CNS, heart, kidney Severe metabolic disorder 	Intensive care: <ul style="list-style-type: none"> Monitor hematocrit, platelets, vitals Treatment of shock: Normal saline bolus Blood transfusion for severe bleeding or clinical worsening. Judicious use of platelets Supportive treatment for organ failure Watch for signs of fluid overload, and treat, if detected (oxygen 2, frusemide)

*Warning signs: Abdominal pain, persistent vomiting, mucosal bleed, hepatomegaly, clinical fluid accumulation, lethargy, hemoconcentration, thrombocytopenia

**Comorbid conditions include hypertension, diabetes, thyroid illness, renal disease, hemoglobinopathy, hepatitis, and heart disease.

Moderate Dengue: Close Monitoring and Hospital Management

Any patient who fulfills the admission criteria should be admitted (as mentioned above). They may or may not have warning signs. A baseline Hct is measured and monitoring is started. In cases where no warning signs are present, patients should be started on maintenance fluids with isotonic fluid. If patient shows signs of mild dehydration, a correction of 50 mL/kg (<12 months) and 30 mL/kg (>12 months) is added to main fluid. At all times, clinical parameters are closely monitored and correlated with Hct to guide further fluid therapy. For those who present with warning signs, the following is advised (**Flowchart 2**):

- Start isotonic IV fluids (normal saline or Ringer's lactate) at 6 mL/kg/h for 1–2 hours
- Reassess Hct and clinical status:
 - If improvement occurs, decrease to 3 mL/kg/h for 2–4 hours, and then continue with 1.5 mL/kg/h for 2–4 hours
 - If clinical status worsens or Hct rises, increase rate of fluids to 10 mL/kg/h for 1–2 hours
- Reassess clinical status, repeat Hct, and review fluid infusion rates, till the child is better
 - If the child improves, maintain minimum IV fluids at 1.5 mL/kg/h for 24–48 hours. Stop fluids when child demands and accepts adequate oral fluids and food.
 - Those who worsen or develop profound shock, bleeding or multisystem involvement, manage as in **Flowchart 3**.

Severe Dengue: Tertiary Level Care

Emergency treatment is required in children with severe dengue or those in critical phase as follows:

- Obtain Hct, blood count, and other organ function tests, as indicated
- Compensated shock:** This stage is characterized by low systolic blood pressure, narrow pulse pressure (<20 mm Hg), and rise in hematocrit (>20%). In these children, fluid resuscitation is started at 10–20 mL/kg/h, and further directed as per **Flowchart 3**.
- Hypotensive shock:** Administer isotonic fluid bolus 20 mL/kg in 15 minutes. For further management, follow the algorithm depicted in **Flowchart 4**. Colloids may be needed in refractory shock. Colloids can be gelatin- or starch-based. They carry theoretical risk of impaired coagulation and allergic reactions. They should be infused slowly with strict monitoring for signs of fluid overload.
- Hemorrhagic complications:** Suspect severe bleeding if there is an unexplained fall in Hct, refractory shock not responding to 40–60 mL/kg of fluid, and persistent or worsening metabolic acidosis. Packed cell transfusion 10 mL/kg over 2–3 hours can be lifesaving in these children. There is not much evidence for platelet transfusion or fresh frozen plasma for severe bleeding. Platelet transfusions should not be used prophylactically. Its use has neither shown to prevent progression to severe bleeding nor does it shorten the bleeding time and may instead be associated with severe side effects. Platelet transfusion should be

restricted to cases with severe bleeding or when platelet counts are below 10,000/mm³. Platelets obtained by single donor apheresis are preferred as they raise the platelet count by 30,000–50,000 as compared to random donor platelets, which result in rise by 5,000–10,000 per unit.

- Monitoring:** This essentially remains the basic prerequisite for treating children with severe dengue, in an emergency setting.
 - Monitor vital signs and peripheral perfusion 1–4 hourly unless patient is out of critical phase. Monitor Hct before and after fluid replacement, then 6–12 hourly.
 - Monitor blood glucose and other organ dysfunction both clinically and biochemically.
 - A typical monitoring chart for dengue fever should record the following: body temperature, heart rate, blood pressure, pulse volume, capillary refill time, abdominal pain, appetite, abdominal pain, vomiting, bleeding, and sensorium.

Treatment of Fluid Overload

A patient with dengue can have fluid overload due to excessive or rapidly transfused IV fluids, use of hypotonic fluids, and inappropriate use of fresh frozen plasma or platelets. Another important reason is continuation of IV fluids even during the phase of plasma reabsorption and recovery.

These children may present with features of pulmonary edema or congestive heart failure. Following management is suggested:

- Oxygen therapy
- Discontinuation or reduction of IV fluids
- Frusemide 0.1–0.5 mg/kg/dose once or twice daily, maintaining serum potassium
- Look for occult hemorrhage and transfuse packed cells

Management of Other Complications

Encephalopathy in dengue may result due to dengue encephalitis, intracranial bleeding, electrolyte disturbances, occlusion due to DIC or hepatic failure. Appropriate diagnosis for cause and specific management should be instituted. Cardiac involvement may be seen during shock or during convalescence, which may manifest as arrhythmias or heart failure.


Criteria for Discharge

Patient should be discharged only if he has been afebrile for at least 24 hours, passing urine normally, having improved appetite, and has no respiratory distress. His laboratory parameters should show a stable Hct and platelet count of >50,000/mm³.

PREVENTION AND CONTROL

Aedes aegypti should be the main target of surveillance and control. As per the WHO report on neglected tropical diseases, the global target is to reduce the case fatality from 0.8% in 2020 to 0% by 2030. The NVBDCP was launched in 2003, which extended vector control

Flowchart 2: Management of moderate dengue.



(Hct: hematocrit; RBC: red blood cell)

Source: National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. (2014). National guidelines for clinical management of dengue fever. [Online] Available from <https://nvbdcp.gov.in/Doc/Dengue-National-Guidelines-2014.pdf> [Last accessed October, 2021].

services for dengue and Japanese encephalitis. A mid-term plan was approved in 2011 to enhance the country's capacity to control dengue. The activities targeted against dengue include:

- Increasing diagnostic facilities. Introduction of ELISA-based NS1 antigen for diagnosis of dengue early in disease.
- Monitoring and surveillance of vector control
- Capacity building of medical health personnel
- Increasing social mobilization through information, education, and communication (IEC) activities for vector control.

Surveillance

Disease Surveillance

Tracking the number of suspected and confirmed infected human cases. It also includes recording the circulating serotypes of dengue and the number of deaths from dengue.

Vector Surveillance

Tracking mosquito populations in areas of potential risk: Mainly two indices are used for measuring the vector density. These are—(1)

house index and (2) Breteau index. House index is defined as the percentage of houses positive for the larvae; and Breteau index as the number of containers positive for the larvae per 100 houses. These indices measure larval infestation rather than adult mosquito density. Epidemic spread of *Aedes* has been reported with house index as low as 1% in Indian settings.


Monitoring Behavioral Impact

Communication for behavioral impact (COMBI) is a methodological process where communication interventions are used to help a community adopt healthy behaviors aimed to reduce mosquito multiplication and spread. The surveillance is done by observing whether such behaviors are adopted and sustained by the community.

Vector Control

The following measures have been advocated as Government advisory to contain vector spread like:

- *Environmental modification*: This includes long-lasting physical transformation of *Aedes* mosquitoes' habitats. Sprays of larvicides are recommended in high-risk localities. Large tanks with taps

Flowchart 3: Algorithm for fluid management in compensated shock.

(SBP: systolic blood pressure; VS: vital signs; Hct: hematocrit; RBC: red blood cell; ABC: airway, breathing, circulation)

Source: National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. (2014). National guidelines for clinical management of dengue fever. [Online] Available from <https://nvbdcp.gov.in/Doc/Dengue-National-Guidelines-2014.pdf> [Last accessed October, 2021].

should be kept covered. Management of roof tops, porticos, and sunshades to be encouraged.


- **Environmental manipulation:** Sensitize and involve the community for detection of *Aedes* breeding places and their elimination. All objects that may collect water (old tyres, broken jars, empty tins, and bottles) should be disposed off. Water should be changed routinely in water coolers, flower vases, and overhead tanks. Coolers, if not in use, should be drained and mopped dry.
- **Changes in human habitations:** Human habitations are to be made mosquito proof by use of mesh on doors/windows. Health education should be provided regularly in schools and through mass media.

Biological and Chemical Control

Use of chemical larvicides, such as *Abate*[®], in big breeding containers has been found useful. Aerosol space spray during daytime may

be another option in high-density areas. Temephos is an effective larvicide when used in a concentration of 1 PPM. This dose has been found safe with low mammalian toxicity. The chemicals that are effective as adulticides for *Aedes* include pyrethrum and malathion. Pyrethrum is used as indoor spray in concentration of 0.1–0.2% at the rate of 30–60 mL/1,000 cubic feet (commercial ready to use preparations are diluted with kerosene). Malathion is used for fogging or ultralow volume sprays.

Use of larvivorous fish in ornamental tanks, fountains, or biocides can kill the larval stages. In recent years, interest in mosquito-killing (entomopathogenic) fungi is reviving, mainly due to continuous and increasing levels of insecticide resistance and increasing global risk of mosquito-borne diseases. Particular focus is on species belonging to the genera *Lagenidium*, *Coelomomyces*, *Entomophthora*, *Culicinomyces*, *Beauveria*, and *Metarhizium*. *Bacillus thuringiensis* serotype H-14 (Bt H-14), an endotoxin producing bacteria, has also been found useful in vector control.

Flowchart 4: Algorithm for fluid management in hypotensive decompensated shock.

(BP: blood pressure; VS: vital signs; Hct: hematocrit; RBC: red blood cell; ABC: airway, breathing, circulation)

Source: National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. (2014). National guidelines for clinical management of dengue fever. [Online] Available from <https://nvbdcp.gov.in/Doc/Dengue-National-Guidelines-2014.pdf> [Last accessed October, 2021].

There has been recent research exploring the control of *Aedes* mosquito by genetically engineering male insects, which carry dominant lethal gene (RIDL) at both pupa and adult stages.

Vaccine Development

A live attenuated tetravalent dengue vaccine (CYD-TDV) has been developed which contains four dengue virus with expression of dengue premembrane and envelope protein and nonstructural and capsid protein of yellow fever strain (YF-17D). The vaccine is administered as three-dose schedule and has shown good protection against

dengue serotype 1, 3, and 4. The vaccine is still under multicentric phase III trials. Early results following 3 years post vaccination have shown a 50–58% reduction in risk for hospitalization among vaccinees. Several research groups are successfully exploring an infectious clone technology for the development of a dengue vaccine. The Chimeri Vax™ system, originally developed to construct JE vaccine, has now been applied to dengue viruses. This vaccine was shown to be safe and immunogenic in a monkey study. Another approach is based on the use of a dengue type 4 mutant containing a deletion for the construction of a dengue chimeric vaccine. Phase I clinical trials of a

deletion mutant carried out in adult humans showed good safety and immunogenicity.

In India, the yeast, *Pichia pastoris*, has been used to develop a noninfectious dengue virus-2 virus-like particle consisting of viral envelope protein using recombinant DNA technology. The vaccine is under trial.



IN A NUTSHELL

1. Dengue is spread by *Aedes* mosquito, which multiplies in collections of stagnated water.
2. Four different serotypes of virus exist. Antibody against one serotype does not confer protection against another. Rather, the illness is more severe following secondary infection in a child sensitized against a different serotype earlier.
3. Increased capillary permeability and coagulopathy chiefly contribute to disease manifestations. Thrombocytopenia occurs both due to bone marrow suppression and immune-mediated destruction.
4. Clinical presentation consists of a biphasic fever, myalgia, arthralgia, and hemorrhagic manifestations, lasting over 3–7 days. The most vulnerable stage is soon after defervescence (critical phase) characterized by increased capillary permeability.
5. Serological diagnosis is possible by detecting nonstructural (NS) antigen 1 between 2 and 5 days, detection of IgM antibodies between 5 and 10 days, or fourfold rise in IgG antibodies after 7–10 days.
6. Children with *warning signs* should be hospitalized. Those with severe shock, severe bleeding, and organ involvement need management in intensive care unit (ICU) setting.
7. Fluid therapy is the mainstay of treatment. Crystalloid is the fluid of choice during resuscitation. Best guide to fluid therapy is Hct.

MORE ON THIS TOPIC

- Akech S, Ledermann H, Maitland K. Choice of fluids for resuscitation in children with severe infection and shock: systematic review. *BMJ*. 2010;341:c4416.
- Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504-7.
- Carod-Artal FJ, Wichmann O, Farrar J, et al. Neurological complications of dengue virus infection. *Lancet Neurol*. 2013;12(9):906-19.
- Chakravarti A, Arora R, Luxemburger C. Fifty years of dengue in India. *Trans R Soc Trop Med Hyg*. 2012;106(5):273-82.

- Chandele A, Sewatanon J, Gunisetty S, et al. Characterization of human CD8 T cell responses in dengue virus-infected patients from India. *J Virol*. 2016;90(24):11259-278.
- Coudeville L, Baurin N, L'Azou M, et al. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine. *Vaccine*. 2016;S0264-410X(16):30735-6.
- Eltom K, Enan K, El Hussein ARM, et al. Dengue virus infection in sub-Saharan Africa between 2010 and 2020: A systematic review and meta-analysis. *Front Cell Infect Microbiol*. 2021;11:678945.
- Gan SJ, Leong YQ, Bin Barhanuddin MFH, et al. Dengue fever and insecticide resistance in *Aedes* mosquitoes in Southeast Asia: a review. *Parasit Vectors*. 2021;14(1):315.
- Ghosh A, Dar L. Dengue vaccines: challenges, development, current status and prospects. *Indian J Med Microbiol*. 2015;33(1):3-15.
- Gupta A, Rijhwani P, Pahadia MR, et al. Prevalence of dengue serotypes and its correlation with the laboratory profile at a tertiary care hospital in northwestern India. *Cureus*. 2021;13(5):e15029.
- Gupta N, Srivastava S, Jain A, et al. Dengue in India. *Indian J Med Research*. 2012;136(3):373-90.
- Kaushik A, Pineda C, Kest H. Diagnosis and management of dengue fever in children. *Pediatr Rev*. 2010;31(4):e28-35.
- Li GH, Ning ZJ, Liu YM, et al. Neurological manifestations of dengue infection. *Front Cell Infect Microbiol*. 2017;7:449.
- National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. (2014). National guidelines for clinical management of dengue fever. [Online] Available from <https://nvbdcp.gov.in/Doc/Dengue-National-Guidelines-2014.pdf> [Last accessed October, 2021].
- National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health & Family Welfare. Guidelines for integrated vector management for control of dengue/dengue haemorrhagic fever. [Online] Available from http://nvbdcp.gov.in/Doc/dengue_1_%20Director_Desk%20DGHS%20meeting%20OCT%2006.pdf [Last accessed October, 2021].
- Rai P, Kille S, Kotian A, et al. Molecular investigation of the dengue outbreak in Karnataka, South India, reveals co-circulation of all four dengue virus serotypes. *Infect Genet Evol*. 2021;92:104880.
- World Health Organization. (1997). Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control. [Online] Available from http://apps.who.int/iris/bitstream/10665/41988/1/9241545003_eng.pdf [Last accessed October, 2021].
- World Health Organization. (2012). Global strategy for dengue prevention and control 2012–2020. [Online] Available from https://www.who.int/immunization/sage/meeting_s/2013/april/5_Dengue_SAGE_Apr2013_Global_Strategy.pdf [Last accessed October, 2021].
- World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: WHO; 2009.

31.20

Chikungunya Fever

Rajniti Prasad

Chikungunya, a viral fever, is caused by an alphavirus [chikungunya virus (CHIKV)] and spread by bite of an infected *Aedes aegypti* mosquito. The disease was first described in 1955 following an outbreak on the Makonde plateau. The name derives from kungunyala, meaning to *dry up or become contorted*. Although primarily African and zoonotic disease, non-African large urban outbreaks have been reported, which is transmitted by the same vectors as those of dengue viruses. Since then, CHIKV has caused numerous outbreaks and epidemics in both Africa and Southeast Asia, affecting many children.

■ CHIKUNGUNYA VIRUS

Chikungunya virus, a positive strand, enveloped RNA (ribonucleic acid) virus, is a member of the alphavirus of *Togaviridae* family. It is closely related to O'nyong-nyong viruses. Three distinct phylogroups were reported on the basis of E1 envelope glycoprotein gene sequence—first contained all isolates from West Africa, second comprised all Central, Southern and Eastern African (CSEA) strains, and third isolates from Asia. Complete genomic sequence of CHIKV has 11,805 nucleotides in length. Coding sequences consist of two

PG Textbook of PEDIATRICS

Highlights of 3rd Edition

- Color-coding to highlight Diagnosis and Treatment Boxes and Tables
- New chapters on Coronavirus-19 disease, Multi-inflammatory syndrome in children, Coronavirus vaccines, Nocturnal enuresis, Screen time, Mucormycosis and Autoinflammatory syndromes
- Inclusion of the Indian Academy of Pediatrics (IAP) 2021 Guidelines and Recommendations on vitamin D and screen time
- Recent data pertaining to child health and nutrition indices from the Comprehensive National Nutrition Survey, National Family Health Survey-5, and Sample Registration System (SRS) 2021
- Introducing the concept of Estimated Average Requirement (EAR) to calculate daily requirement of nutrients against the standard Recommended Dietary Allowance (RDA).

The Book with an Edge...

- Pediatrics in all its complexity and comprehensiveness covered completely in 3 Volumes, 11 Parts, 52 Sections, and 600+ Chapters with India-centric approach and solutions, edited by the foremost experts and doyens in their respective fields
- A genre-establishing book, created by 50 Section Editors and 700+ choicest faculty from more than 200 teaching institutions in India and abroad
- Systemic arrangement of the entire subject in 11 Parts; Starting from Introduction to Pediatrics, Basic Sciences, Intensive Care and Emergencies; moving on to the problems of the Newborn Infant, The Child, and the Adolescent; and culminating with exhaustive treatise on Infectious Disorders, Systemic Pediatrics, Pediatric Subspecialties, and Social Issues in Child Health; followed by Annexures on Drug Formulary and Laboratory values. Each Chapter contains summary points—*In a Nutshell*, and suggested reading—*More on this Topic*
- A MUST for every postgraduate student and practicing pediatrician in India.

Piyush Gupta MD FAMS is a renowned academician, teacher, researcher, author and editor; he has published more than 300 papers, 400 book chapters, and edited/authored 40 books, including *Textbook of Pediatrics*, *Clinical Methods in Pediatrics*, *Essential Pediatric Nursing*, *IAP Textbook of Pediatrics*, *Principles of Medical Education*, and *How to Write a Thesis*. He has served as Editor-in-Chief of 'Indian Pediatrics' (official journal of the Indian Academy of Pediatrics) for 6 years. He has been conferred fellowships by the Royal College of Paediatrics, UK; Indian Academy of Pediatrics; National Neonatology Forum, India; National Academy of Medical Sciences, India; and awarded by the American Academy of Pediatrics for his work on micronutrients. His major initiatives include workshops on thesis and scientific paper writing; and increasing awareness for practicing rational management of diarrhea and pneumonia in children. He has served as technical expert/advisor to the Government of India, World Health Organization (WHO), the United Nations Children's Fund (UNICEF), and the Indian Council of Medical Research (ICMR). He has delivered 34 orations, including the prestigious KL Wig Oration in the field of Medical Education in India. He has served as the Joint Secretary of South Asia Pediatrics Association. He is serving on the editorial board of several national and international journals. He has been awarded as the *National Teacher of Excellence* by the Vice-President of India. In 2021, he served as the National President of Indian Academy of Pediatrics.



PSN Menon MD MNAMS is a distinguished endocrinologist, teacher, and researcher; he has served as the Sub-Dean and Professor of Pediatrics at the All India Institute of Medical Sciences (AIIMS), New Delhi, India and the Consultant-in-charge of the Pediatric Endocrinology and Officer-in-charge of the World Health Organization (WHO) Regional Research and Training Centre in Genetics for the SEARO at AIIMS. He has over 150 original research publications in reputed and indexed journals and has edited textbooks in the field of pediatrics and pediatric endocrinology including *IAP Textbook of Pediatrics* and *Pediatric Endocrine Disorders* and contributed chapters for textbooks for undergraduates and postgraduates. He was the President of the Indian Society for Pediatric and Adolescent Endocrinology (ISPAE) and Member of the Executive Council of the Asia Pacific Paediatric Endocrine Society (APPEs). He is on the editorial board of several prestigious journals in the field of pediatrics, diabetes, and endocrinology.



Siddarth Ramji MD FNNF is an eminent neonatologist, academician, and researcher; his primary interest has been perinatal asphyxia, neonatal resuscitation, and low birth weight. He has been involved in pioneering research in neonatal resuscitation. He has been a Chair of the Committee of Technical Experts for Referral Care of Sick Newborn and Child, and is a Member of the Task Force on Child Health of the Ministry of Health, Government of India. He is currently the Executive Editor of *Indian Pediatrics* and has to his credit almost 100 research publications. He has been on several task forces and committees that have been involved in formulating Neonatal Health Policy in India.



Rakesh Lodha MD is an acclaimed intensivist and researcher, he is currently heading the Pediatric Intensive Care Unit at All India Institute of Medical Sciences (AIIMS), New Delhi, India. He has more than 480 research publications, has authored 10 books and more than 125 book chapters. He is actively involved in the training of healthcare personnel in critical care and infectious diseases and conducted multiple clinical trials. He is also the Associate Editor of *Indian Pediatrics*; Editor, *Indian Journal of Pediatrics*; and Associate Editor, *National Medical Journal of India*. He is particularly interested in teaching of research methods. He has also been involved in various public health programs globally and nationally. His primary interests include pediatric intensive care, pulmonology, and infectious diseases.



Printed in India

Available at all medical bookstores
or buy online at www.jaypeebrothers.com



JAYPEE BROTHERS
Medical Publishers (P) Ltd.
EMCA House, 23/23-B, Ansari Road,
Daryaganj, New Delhi - 110 002, INDIA
www.jaypeebrothers.com

Join us on [facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)

Shelving Recommendation
PEDIATRICS

ISBN 978-93-5465-121-2

